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ABSTRACT 
 
MILEKA RICHELLE GILBERT:  Dendritic cell and Macrophage-Mediated Tolerance in 
Lupus-Prone Mice 
(Under the direction of Barbara Vilen) 
 
During infection, immune cells respond to polyclonal activators, like bacterial and viral 
antigens, through innate immune responses.  Therefore, mechanisms to regulate the 
activation of autoreactive B cells during polyclonal activation are necessary to prevent 
autoimmunity.  Previous studies into the mechanisms of B cell tolerance have focused on B 
cell Receptor (BCR)-mediated regulation of autoreactive or chronically antigen-experienced 
B cells.  However, the regulation of chronically antigen-experienced B cells during 
polyclonal activation is less understood.  We recently identified a novel mechanism of 
tolerance wherein DCs and Ms repress Ig secretion by autoreactive B cells.  Polyclonal 
activators through Toll-like Receptors (TLRs) induce DCs and Ms to secrete soluble 
factors (IL-6, sCD40L, and TNF) that differentially regulate naïve and chronically antigen-
experienced B cells.  IL-6, sCD40L, and TNF selectively repress chronically stimulated 
autoreactive B cells while having no effect on naïve B cells.  Thus, we have identified a 
mechanism that prevents autoimmunity while allowing naïve B cells to respond during innate 
immune responses.  Significantly, TLR-activated DCs and Ms from lupus-prone mice are 
defective in repressing autoreactive B cells, coincident with defects in IL-6, sCD40L, and 
TNF secretion.  This could allow autoreactive B cells to secrete autoantibodies during 
innate immune responses, promoting autoimmune disease in lupus-prone mice.  Determining
iv
the TLR defect in DCs and Ms from lupus-prone mice could identify a genetic signature 
for individuals susceptible to lupus disease.
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CHAPTER I 
Introduction 
 
21.1  Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a multiorgan autoimmune disease 
characterized by the production of autoantibodies to nuclear components, including DNA and 
Smith antigen (Sm).  Autoantibodies contribute to pathology either by directly binding tissue 
antigen or by forming immune complexes which activate complement or bind Fc receptors 
inducing inflammation (1).  Symptoms and severity of disease vary but include malar or 
discoid rash, arthritis, glomerulonephritis, vasculitis, neurologic and hematologic disorders.   
SLE afflicts up to 1.5 million people in the United States, with both genetic and 
environmental factors associated with disease.  90% of SLE patients are women, and disease 
disproportionately affects African-Americans.  Ethnic background correlates with the 
production of certain autoantibodies and has been associated with different clinical and 
laboratory features of SLE.  Several studies have linked autoantibodies against dsDNA, Sm, 
Ro, and phospholipids with increased disease damage in different ethnicities (2-9).  The 
concordance of disease in identical twins is 25-50% compared to around 5% in dizygotic 
twins, and polymorphisms and homozygous deficiencies in some genes increases the risk of 
developing SLE (10).  For example, HLA DR2 and DR3 and certain polymorphisms in TCR, 
FcR, IL-6, and TNF genes increase risk of disease (10).  In addition, deficiencies in 
DNaseI (11) and complement C2, C4, and C1q (10) are highly associated with SLE.  These 
observations suggest a strong genetic component of disease; however, most cases of SLE are 
sporadic.  It is thought that environmental factors trigger disease or flare-ups in susceptible 
individuals.  Certain drugs, infectious agents (especially Epstein Barr virus), and excess 
estrogens have been linked to disease (12).  The interaction of these environmental factors 
3with predisposed genetic backgrounds could explain the heterogeneity in disease symptoms 
and severity. 
Autoimmunity results from a breakdown in tolerance mechanisms that regulate 
autoreactive lymphocytes (10, 13).  The breakdown of B cell tolerance mechanisms 
ultimately leads to the production of autoantibodies against nuclear components and immune 
complexes that are linked to the pathology of disease (10, 13).  The etiology of SLE remains 
unknown; however, investigation into the breakdown of tolerance mechanisms has provided 
valuable insight into the causes of disease.  SLE patients are unable to effectively clear dying 
cells, and thus exhibit an increased burden of apoptotic cells that serve as a source of nuclear 
antigens (14-17).  The dysregulated presence of apoptotic cells promotes autoimmunity, and 
recently been shown to induce nephritis in mice (18).  Currently, the standard of care for SLE 
is immunosuppressive or anti-inflammatory drugs, with recent therapies focusing on B cell 
depletion.  Understanding the mechanisms that regulate autoreactive B cells would lead to 
more specific therapies that re-establish tolerance in SLE patients. 
 
1.2  Mechanisms of B cell Tolerance
B cell development begins in the bone marrow where immature B cells generate B 
cell receptors (BCR) with diverse specificities.  Tolerance mechanisms are critical in 
regulating the estimated 50-75% of newly produced B cells with autoreactive specificity in 
the bone marrow in order to prevent autoimmune disease (19).  The study of these 
mechanisms began with the creation of immunoglobulin (Ig) transgenic mice, which 
increases the frequency of B cells having one specificity, thereby providing a tool to follow 
the development and regulation of autoreactive B cell clones in vivo. Using Ig transgenic 
4mice, several mechanisms of tolerance have been identified, including clonal deletion, 
anergy, positive selection into the B1 compartment, receptor editing, and ignorance. 
 
A.  Clonal deletion, anergy, and positive selection into the B1 compartment. The first 
reports describing B cell tolerance used anti-H-2k and anti-hen egg lysozyme (HEL) Ig 
transgenic models to identify clonal deletion and anergy as mechanisms of tolerance.  The H-
2k Ig transgenic model described deletion of autoreactive B cell clones in the bone marrow.  
In this model, an H-2d mouse expressing an H-2k specific B cell receptor (BCR) was crossed 
to an H-2k mouse (20).  The resulting mice lack anti-H-2k B cells and serum anti-H-2k
antibody, in contrast to their H-2d transgenic naïve counterpart that exhibits anti-H-2k serum 
titers.  The data suggest that these anti-H-2k B cells are deleted in the bone marrow, and that 
autoreactive B cells are regulated by clonal deletion (20).  However, Goodnow et al reported 
that anti-HEL B cells are regulated by another mechanism of tolerance.  The authors created 
a double transgenic mouse expressing soluble HEL (sHEL) and the rearranged Ig heavy and 
light chain genes encoding a high affinity anti-lysozyme antibody (anti-HEL) (21).  Anti-
HEL B cells are present in the spleen but do not secrete Ig spontaneously, nor when 
stimulated with antigen in the presence of T cell help.  In addition, anti-HEL B cells 
chronically exposed to sHEL downregulate membrane IgM, unlike naïve anti-HEL B cells 
(21).  Further, unresponsiveness to HEL requires that a threshold number of receptors be 
occupied (22). Antigen-binding B cells normally migrate into lymphoid follicles where they 
receive survival signals.  However, autoreactive B cells exposed to sHEL are excluded from 
the follicle, resulting in their premature death (23).  The data indicate that autoreactive B 
cells in the periphery exist in a functionally silenced state termed anergy.  Thus, these initial 
5reports determined that autoreactive B cells generated in the bone marrow can be clonally 
deleted, but some escape into the periphery where they are regulated by anergy. 
To understand why some autoreactive B cells are regulated by deletion versus anergy, 
the HEL model was used to alter the presentation of self-antigen.  When sHEL is modified to 
encode an integral membrane protein (mHEL), mature B cells in the periphery are deleted 
(24).  Subsequent experiments revealed that the elimination of anti-mHEL B cells proceeds 
in two stages.  Upon initial encounter with self-antigen, developmental arrest occurs and B 
cells are deleted within 1-3 days (25).  Thus, membrane-bound antigen induces deletion, 
whereas soluble antigen induces anergy.  In addition to the form of antigen, cellular location 
can determine whether autoreactive B cells are deleted.  HEL was modified to contain an 
endoplasmic reticulum retention signal (ER-HEL), sequestering antigen intracellularly.  
Unlike mHEL that causes deletion of B cells, ER-HEL positively selects B cells to 
differentiate into B1 cells (26).  Collectively, the data show that the induction of deletion or 
anergy depends on the cellular location of antigen and the ability of antigen to crosslink 
receptors providing a stronger stimulus.  The role of BCR affinity remains unclear.   
 
B.  Clonal deletion and anergy regulate B cells specific for disease-associated antigen. 
The HEL and H-2k models of tolerance proved to be invaluable in the early description of 
clonal deletion and anergy; however, one weakness is in their use of non-disease associated 
antigen.  A transgenic model of autoimmune hemolytic anemia demonstrated that both 
deletion and anergy can regulate autoreactive B cells within the same mouse (27).  Several 
models of tolerance exist to study the regulation of autoreactive B cells specific for lupus-
associated antigens. 
6The majority of SLE patients have high anti-dsDNA serum titers and anti-dsDNA has 
been shown to cross react with the kidney protein -actinin.  To study the mechanisms that 
regulate anti-DNA B cells, the VH3H9 Ig heavy chain transgenic mouse was created (28).  
These mice do not exhibit anti-DNA serum titers higher than wildtype animals, indicating 
that regulatory mechanisms prevent the production of autoantibodies.  The VH3H9 heavy 
chain can pair with multiple light chains to form antibodies of both ss- and dsDNA 
specificity.  However, only anti-ssDNA, and not anti-dsDNA, B cells exist in the periphery.  
Collectively, the data suggest that anti-dsDNA B cells recognize self-antigen and are deleted, 
whereas anti-ssDNA B cells escape into the periphery but exist in an anergic state (28).  
Anti-ssDNA B cells from VH3H9/V8 double transgenic mice are anergic, yet they do not 
down-regulate IgM unlike anergic anti-HEL B cells (28, 29).  These cells show suboptimal 
proliferation in response to BCR and LPS stimulation; however, their turnover rate is similar 
to non-transgenic B cells (29).  Thus, deletion and anergy exist in the anti-DNA model, and 
down-regulation of IgM is not always associated with anergy. 
The regulation of anti-ssDNA B cells is studied in the Ars/A1 transgenic mouse
where anti-p-azophenylarsonate (Ars) BCR cross reacts with ssDNA. There is no evidence
of clonal deletion or receptor editing in the bone marrow, although these B cells have seen
self-antigen. Mature B cells exist in an anergic state in the periphery, as determined by lack
of calcium mobilization, tyrosine phosphorylation, and antibody production in response to
BCR stimulation (30).
Anti-Sm titers are specific for lupus and correlate with poor prognosis. To study the
regulation of anti-Sm B cells, 2-12 heavy chain Ig transgenic mice were generated. The 2-12
heavy chain pairs with multiple light chains to create Sm and ssDNA-specific B cells, as well
as non-autoreactive specificities. Similar to other tolerance models, Sm-specific B cells are
7present in the periphery, exhibit shortened lifespans, but fail to secrete autoantibodies (31).
In addition, functional anti-Sm B cells are positively selected into the peritoneal cavity and
differentiate into B1 cells (32). These cells secrete anti-Sm upon immunization with snRNPs
(31). Thus, transgenic mice harbor functional and non-functional anti-Sm B cells. To study
low-affinity anti-Sm B cells, 2-12 heavy chain Ig transgenic mice were crossed with V8
light chain transgenic mice (33). 2-12H/V8 antibodies have low affinity for Sm and do not
bind ssDNA or dsDNA. Low-affinity Sm-specific B cells are found in the peripheral
lymphoid organs and do not differentiate into B1 cells. They are unresponsive to LPS, do not
down-regulate IgM, and fail to be excluded from the B cell follicle. This demonstrates a
unique phenotype compared to other models (33). Anergic anti-Sm B cells in the spleen are
regulated at an early pre-plasma cell stage, defined by intermediate expression of CD138 and
normal levels of CD19 and B220. The tolerance checkpoint occurs upstream of Blimp-1
control of plasma cell differentiation (34).
C. Receptor editing. The anti-H-2k (35) and anti-DNA (36, 37) models identified receptor
editing as another mechanism of tolerance. Analysis of anti-DNA B cells showed that
rearrangement of the endogenous light chain genes occurs, and they successfully compete
with the transgenic light chain for heavy chain binding. As a result, a nonautoreactive
receptor is created, thereby allowing the B cell to escape deletion (36).
D. Lack of T cell help. Antigen-stimulated B cells require T cell help to produce Ig.
Activated T cells induce surface CD40 ligand (CD40L) expression, and lack of CD40L or
blocking CD40 stimulation on B cells impairs Ig production (38). Anergic B cells can
overcome tolerance by providing T cell help. In VH3H9/1 Ig transgenic mice, anti-dsDNA
8B cells are held at the T-B interface. Injection of a source of cognate T cells leads to the
migration of anti-dsDNA B cells into the B cell follicle and production of autoantibody (39).
Thus, lack of T cell help is also a tolerance mechanism. However, the situation is somewhat
different for anergic HEL-specific B cells. These B cells do not respond to antigen and T cell
stimulation (40). T-dependent Ig responses require B cell signaling for the B cell to interact
with the T cell and receive T cell help. Significantly, anergic HEL-specific B cells exhibit a
block in sHEL-mediated BCR signaling (40) and decreased up-regulation of costimulatory
molecules (41), and thus can not activate T cells to provide help. However, they respond
normally to IL-4 and anti-CD40 stimulation in vitro, indicating that they are still capable of
responding to T cell help. Stimulation with the more potent mHEL antigen triggers the BCR
to signal, thereby restoring their ability to respond to T cell help and secrete Ig (40). The
absence of T cell help could result from the deletion of autoreactive cognate T cells by
central tolerance mechanisms in the thymus or CD4+CD25+ regulatory T suppression of CD4+
helper T cells. Some evidence shows that regulatory T cells can also directly suppress B cell
Ig production (42).
In summary, several mechanisms of tolerance regulate B cells specific for self-antigens.
Central tolerance mechanisms such as deletion and receptor editing regulate immature B cells
specific for high avidity, membrane-bound self-antigens (20, 24, 27, 35, 36). Peripheral
tolerance mechanisms regulate bone marrow emigrants through deletion (37), positive
selection into the B1 compartment (26, 32), functional ignorance of low affinity antigens (43,
44), lack of T cell help (38), and anergy (22, 28, 30, 33, 40). Some anergic B cells display
BCR signal transduction defects with diminished induction of phosphotyrosine yet elevated
intracellular Ca2+ and constitutive ERK activation (45). Anergic cells exhibit reduced surface
9IgM (21), decreased lifespan (23), and exclusion of B cells from the follicle (23, 46). These
findings lead to a model wherein BCR affinity coupled with the abundance, location, and
avidity of self-antigen dictates the fate of autoreactive B cells (26, 47).
1.3  Loss of Tolerance in Autoimmune Mice
A.  Mouse models of lupus. Regulating autoreactive B cell secretion of Ig is crucial in 
preventing lupus.  To better understand human disease, murine models of SLE are used to 
study the defects in B cell tolerance mechanisms that lead to disease.  Several strains of 
lupus-prone mice were generated as spontaneous serendipitous products of mouse breeding.  
The MRL strain resulted from the combination of four nonautoimmune strains: LG, C3H, 
C57BL/6, and AKR (48).  During the breeding at Jackson Laboratories, a spontaneous 
mutation in the lpr gene occurred, resulting in a defective Fas receptor.  MRL/lpr mice 
produce several autoantibodies specific for SLE, including anti-dsDNA, anti-Sm, anti-Su, 
and anti-ribosomal P.  As a result, mice develop a systemic autoimmune syndrome consisting 
of vasculitis, dermatitis, and immune complex-mediated glomerulonephritis with 
proliferative changes in the glomeruli and Ig and complement deposition.  Mice also exhibit 
lymphadenopathy due to the accumulation of CD4-CD8- T cells and increased numbers of 
CD4+ T cells, CD8+ T cells, and B cells.  Although there seems to be no general defect in 
deletion of autoreactive lymphocytes in lupus-prone mice (49, 50), massive 
lymphoproliferation may reflect the lack of a functional Fas receptor potentially preventing 
negative selection and clonal deletion through apoptosis.  Median survival of MRL/lpr mice 
is 5 months.  Without the lpr gene, the MRL strain still produces autoantibodies, but the 
development of lupus disease is delayed to about 1 year.  Yet, the lpr gene is sufficient in 
causing autoimmunity as backcross onto nonautoimmune backgrounds leads to autoantibody 
10
production.  Thus, the MRL/lpr lupus mouse model exhibits several characteristics consistent 
with human disease. 
B.  Breakdown of B cell tolerance in lupus-prone mice. In order to study the breakdown 
of tolerance mechanisms, Ig transgenes were backcrossed onto autoimmune backgrounds to 
identify the steps leading to autoantibody production.  Like human SLE (75%) (51), the 
majority of MRL/lpr mice (>90%) (48) develop anti-dsDNA antibodies.  To study how anti-
DNA B cells break tolerance in lupus, the Ig heavy chain VH3H9 transgene was bred onto 
the MRL and MRL/lpr backgrounds.  VH3H9 transgenic B cells produce anti-DNA 
antibodies that stain nuclei in a homogenous nuclear (HN) fashion.  VH3H9 trangenic 
MRL/lpr are seropositive by 3 months, while nonautoimmune transgenic mice actively delete 
anti-HN B cells (52).  MRL/lpr mice fail to delete anti-HN B cells, and these cells undergo 
preferential clonal expansion.  In addition, the VH3H9 transgene is less efficient at inhibiting 
heavy chain gene rearrangement on the autoimmune versus the nonautoimmune background 
(53).  Somatic mutation and peripheral light chain rearrangement in anti-ssDNA B cells from 
transgenic MRL/lpr mice can generate pathogenic anti-dsDNA antibodies (54), 
demonstrating that receptor editing occurs in the periphery.  The VH3H9 Ig heavy chain 
paired with the V1 light chain is specific for dsDNA, allowing the ability to follow dsDNA 
antibodies specifically in the VH3H9 transgenic mouse.  Before seroconversion, anti-dsDNA 
B cells in MRL and MRL/lpr mice exhibit a defect in maintaining developmental arrest, as 
they express levels of B220, HSA, CD22, and CD44 comparable to mature cells.  In addition, 
anti-dsDNA B cells in MRL/lpr but not MRL mice are present in the splenic follicle (55).  
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Thus, the MRL background and lpr gene allow anti-dsDNA B cells to break tolerance, 
differentiate to antibody secreting cells, and produce autoantibody. 
The prevalence of anti-Sm in human SLE and MRL/lpr mice is 25% (48, 51).  To 
study how anti-Sm B cells break tolerance in lupus, the 2-12 Ig heavy chain was backcrossed 
onto MRL/lpr mice to increase the prevalence and frequency of anti-Sm B cells.  The 
presence of the transgene accelerates the anti-Sm response and increases the prevalence of 
anti-Sm titers from 25% to 100% (56).  Anti-Sm B cells are more activated and express 
higher levels of CD44, CD40, CD80, and CD86.  The frequency of transitional anti-Sm B 
cells is similar to nonautoimmune mice.  However, there are very few peritoneal anti-Sm B-1 
cells in 2-12H transgenic MRL/lpr mice, suggesting that a defect in B-1 differentiation may 
be a factor in the loss of tolerance to Sm (56).  The CD138int pre-plasma cell stage was 
identified as a tolerance checkpoint in anti-Sm B cells (34).  MRL/lpr mice exhibit an 
increased frequency of CD138int B cells that secrete Ig, and anti-Sm CD138int cells are more 
activated and differentiated than nonautoimmune mice.  Moreover, anti-Sm B cells in 2-12 
heavy chain transgenic MRL/lpr mice differentiate to CD138hi pre-plasma and plasma cells, 
where they are absent on the nonautoimmune background (34).  Thus, anti-Sm B cells break 
tolerance in MRL/lpr mice by progressing through the CD138int checkpoint differentiating 
into antibody-secreting plasma cells. 
 
C.  Apoptotic cells and the break in tolerance. The role that apoptotic cells play in 
regulating the immune system is a critical issue in SLE considering that an increased burden 
of apoptotic cells is associated with both human and murine lupus (14-16, 57, 58).  Further, 
mice deficient in the mer, axl, and tyro3 receptor tyrosine kinases involved in the signaling 
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and phagocytosis of apoptotic cells develop a severe lymphoproliferative disorder and a 
lupus-like disease (59-62).  Injection of apoptotic cells in mer deficient mice induces a 
chronic anti-Sm response (63).  Preliminary data also show that chronically antigen-
experienced B cells from Ig transgenic 2-12H/V8 mice spontaneously break tolerance when 
on a mer deficient background and exhibit a positive anti-Sm titer (Kilmon and Vilen, 
unpublished observations).  Thus, the link between lupus and the inability to signal and/or 
phagocytose apoptotic cells through tyro 3 family tyrosine kinases is well established.   
 
D.  SLE congenic mice. Understanding the molecular defects that drive autoreactive B cells 
through tolerance checkpoints is critical in understanding the etiology of SLE.  Several 
groups have approached this problem by studying the phenotypic effects of lupus 
susceptibility loci using congenic mice (64, 65).  Interval mapping of F2 mice intercrossed 
between MRL/lpr and B6.lpr identified four loci (Lmb1-4) linked to lymphadenopathy and 
splenomegaly.  Lmb1, Lmb2, and Lmb3 are also associated with the production of anti-
dsDNA, and Lmb4 is associated with glomerulonephritis (66).  Nba2, Nba5, and Sgp3 loci, 
derived from the NZB lupus strain, are anti-gp70 autoantibody production, gp70 immune 
complex formation, and glomerulonephritis (67).  Nba2 alone increases the proportion of 
activated B cells and anti-ssDNA antibody production (68).  The Sle congenic mice were 
derived from the NZM2410 lupus model.  The Sle1 locus is associated with increased 
activation of CD4+ T cells that provide help to anti-chromatin B cells.  Significantly, Sle1a 
and Sle1c are associated with decreased numbers of CD4+CD25+ regulatory T cells that 
precedes autoantibody production (69).  Sle1ab splenic ex vivo B cells are aberrantly 
activated compared to wildtype, as demonstrated by upregulation of B cell activation marker 
13
CD69, increased phosphorylation of STAT3 and ERK, and increased IL-6 production (70).  
These data indicate that the Sle1 locus causes a break in T cell tolerance that could contribute 
to the activation of autoreative B cells.  Other studies showed that Sle3 contributes to defects 
in DCs and Ms and in Ig gene recombination.  B6.Sle3-derived DCs and Ms are more 
activated and better co-stimulators of T cells (71).  Sle3/5 affects somatic Ig heavy chain 
diversification and led to recombination of allelically excluded Ig heavy chain genes in the 
periphery, possibly contributing to the development of autoreactive B cell repertoires (72). 
 
Hence, murine models of lupus and congenic mice carrying lupus susceptibility loci have 
provided valuable insight into the breakdown of tolerance causing disease. 
 
1.4  Toll-like Receptors in SLE
The tolerance mechanisms described above address the regulation of autoreactive B 
cells in the periphery during T-dependent immune responses and describe tolerance mediated 
by antigen/BCR.  However, flare-ups in SLE have been associated with infectious agents that 
polyclonally activate immune cells.  Significantly, many of the autoantibodies associated 
with lupus react against nuclear antigens that also bind Toll-like Receptors (TLRs) important 
in innate immune responses.  Thus, polyclonal activation of immune cells during innate 
immunity may contribute to SLE pathogenesis. 
 
A.  Characteristics of TLRs. TLRs play a major role in bridging the innate and adaptive 
immune responses.  The Toll signaling pathway was originally described in the anti-fungal 
immune response in Drosophila (73) and parallels signaling through the IL-1 receptor in 
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mammalian cells (74).  Identification of the human homolog to the Drosophila Toll protein 
confirmed that the Toll signaling pathway is an important evolutionarily conserved innate 
immune response (75).  Toll is a transmembrane protein with an extracellular domain 
consisting of a leucine-rich repeat domain and a cytoplasmic domain homologous to that of 
the IL-1 receptor (75).  There have been 10 TLRs identified in humans and approximately 13 
in mice responding to different bacterial and viral components (also called pathogen-
associated molecular patterns-PAMPs), including LPS (TLR4), CpG oligonucleotides 
(TLR9), dsRNA (TLR3), and viral ssRNA (TLR7).  TLRs are found mostly on the cell 
surface in the plasma membrane, except for TLR3, TLR7, and TLR9 that are located on the 
membranes of intracellular endosomes (76-78). 
 
B.  TLRs and autoimmunity. Only recently has the role of innate immunity in tolerance 
and autoimmunity been investigated.  Mice deficient in the key TLR signaling adaptor 
molecule MyD88 are not susceptible to autoimmune diseases like celiac disease and 
autoimmune myocarditis, uveitis, and encephalomyelitis (79-82), suggesting the involvement 
of TLRs in causing disease.  In vitro studies suggest that TLR9 is required for activation of 
rheumatoid factor (RF) B cells through anti-chromatin immune complexes (83), and showed 
that dual ligation of TLR9 and BCR activates anti-chromatin B cells (84).  Additionally, 
TLR7 is required for optimal proliferation of B cells specific for RNA-containing antigens 
(85).  Studies in vivo tell a more complicated story.  Production of anti-chromatin antibodies, 
but not anti-dsDNA or anti-Sm-RNP, in TLR9-deficient MRL/lpr mice is diminished; yet, 
these mice exhibit worse disease accompanied by more activated lymphocytes and 
plasmacytoid DCs and increased serum IgG and IFN (86, 87).  Similarly, TLR9 in the 
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absence of FcRIIB is required for class switching to pathogenic anti-DNA antibodies (88).  
Another study showed that TLR9-deficient MRL and MRL/lpr mice develop more severe 
disease.  However, unlike the previous studies, anti-dsDNA, anti-ssDNA, and RF antibody 
production is increased (89).  These studies suggest that TLR9 is protective against lupus, 
and the effect on autoantibody production is controversial.  On the other hand, one study 
using alternative methods suggests that TLR9 promotes lupus.  Injection of CpG DNA 
triggers lupus nephritis in MRL/lpr mice accompanied by increased B cell proliferation, B 
cell production of IL-12, anti-dsDNA production, and DC IFN production (90).  TLR7 has 
also been implicated in lupus pathogenesis.  TLR7-deficient mice are protected from disease 
having decreased activation of lymphocytes and serum IgG production (86), suggesting that 
TLR7 promotes lupus disease.  Although the exact role of TLRs in disease is complicated 
and controversial, the presence or absence of certain TLRs and stimulation through these 
receptors are indeed having an effect.  Thus, research into the role of TLRs in tolerance and 
autoimmunity is critical in understanding SLE. 
 
1.5  Toll-like Receptors in Innate Immunity
A. TLR signaling pathways. TLRs and their signaling pathways are generally characterized 
as MyD88-dependent (TLR7 and TLR9) or TRIF-dependent (TLR3).  The exception is 
TLR4 which utilizes both MyD88 and TRIF-dependent pathways.  In the MyD88-dependent 
pathway, ligand binding induces MyD88 association with TLR, which recruits IRAK4 and 
IRAK1.  IRAK4 subsequently phosphorylates IRAK1 and recruits TRAF6 to the receptor 
complex.  Activated IRAK1 and TRAF6 dissociate from the receptor and IRAK1 is 
degraded.  TRAF6 is degraded in the cytosol, which leads to TAK1 phosphorylation of MAP 
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kinases and the IKK complex.  MAP kinases (ERK, JNK, and p38) activate the transcription 
factor AP-1.  The IKK complex phosphorylates IB, causing IB degradation and release of 
the transcription factor NF-B.  NF-B then translocates to the nucleus where it induces 
transcription of inflammatory cytokines and costimulatory molecules (77, 78, 91-95).  The 
TRIF-dependent pathway, ligand binding induces the association of TRIF with TLR.  This 
activates IKK and TBK1, which activate IRF3.  Phosphorylation of IRF3 promotes it to 
dimerization and nuclear translocation.  IRF3 dimers induce transcription of IFN- and IFN-
inducible genes.  TRIF also induces TRAF6 activation, leading to IB phosphorylation and 
late phase NF-B activation (77, 78, 91, 92, 96).  A defect in the activation of any of these 
signaling effectors or transcription factors could lead to defective cytokine secretion in 
response to TLR stimulation. 
 
B.  Negative regulation of TLR signaling. Regulation of TLR signaling is important in 
controlling inflammation.  Endotoxin tolerance has been described in monocytes and 
macrophages as a mechanism to control responses to bacteria prevent overwhelming 
inflammation.  Pretreatment with LPS induces SHIP phosphatase activity and decreases 
phosphorylation of ERK, JNK, p38, and IB, preventing activation of AP-1 and NF-B
transcription factors.  Subsequently, cells are rendered refractory to further TLR stimulation 
(97-103). 
Other negative regulators of TLR responses have been described that bind early 
signaling intermediates and block further propagation of signal.  The flightless I homolog 
prevents MyD88 from associating with TLR4 (104).  MyD88 short (MyD88s) blocks the 
association of IRAK4 with MyD88.  IRAK-M prevents the dissociation of the IRAK1-
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IRAK4 complex from the receptor (91).  Monarch-1 was the first CATERPILLER protein 
described to antagonize TLR signaling by preventing IRAK-1 phosphorylation and activation 
(105).  MAPK phosphatase-1 and PI3K regulate TLR signaling by blocking activation of the 
MAPK p38 (106-109). 
Suppressor of cytokine signaling (SOCS)-1/3 proteins inhibit cytokine and LPS 
signaling (110-114).  These proteins are induced by the inflammatory signals they inhibit 
creating an autoregulatory feedback loop that functions to control inflammation.  
Specifically, IL-10, IFN, IL-6, and LPS induce SOCS1 and SOCS3 in a STAT dependent or 
independent manner, and SOCS proteins prevent LPS induced cytokine production (111-113, 
115-117).  Little is known about how SOCS proteins inhibit TLR signaling.  Frobose et al 
showed that SOCS3 inhibits IL-1 signal transduction by inhibiting ubiquitination of TRAF6, 
thus preventing association and activation of TAK1 (118).  SOCS1 inhibition of LPS 
signaling involves several mechanisms.  SOCS1 associates with TLR molecules IRAK (111) 
and Mal (116).  SOCS1 also inhibits phosphorylation of Jak2 and STAT5 involved in NF-B
activation (119). 
In summary, several molecules and mechanisms exist that regulate innate immune 
responses mediated by signaling through TLRs. 
 
1.6  Dendritic Cells and Macrophages Link Innate and Adaptive Immune Responses
Dendritic cells (DCs) and macrophages (Ms) are professional antigen presenting 
cells characterized by location, cell surface phenotype, and function in directing immune 
responses or immune tolerance.  They are important in linking the innate and adaptive 
immune responses through phagocytosis of infectious material or necrotic and apoptotic 
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cells, activation of TLRs, and presentation of intact or processed antigen to B cells and T 
cells respectively.  Ms also act as chronic inflammatory cells to clear cellular debris in the 
resolution of inflammation. 
 
A.  DC activation of T cells. There are several subpopulations of DCs; however those that 
help to direct immune responses in the spleen include myeloid DCs (myDCs), lymphoid DCs 
(lyDCs), and plasmacytoid DCs (pDCs) (120-122).  MyDCs (CD11chi/CD11b+/CD8-/CD4+/-)
make up the majority of DCs in the spleen, while lyDCs (CD11chi/CD11b-/CD8+/CD4-) and 
pDCs (CD11clo/CD11b-/CD4+/B220hi) comprise only a small portion of splenic DCs.  
Antigen stimulation of myDCs leads to a Th2-type T cell response through the production of 
IL-4, IL-5, and IL-10, whereas antigen-stimulated lyDCs secrete IL-2, IL-12, and IFN
inducing a Th1-type T cell response (123, 124).  pDCs induce T cell activity by secreting 
IFN in response to viral stimulation (122, 125). 
Innate stimulation through TLR in DCs drives adaptive immunity in several ways.  
LPS induces functional maturation in DCs by upregulating surface expression of MHC Class 
II, CD40, CD80, and CD86 costimulatory molecules and inflammatory cytokine secretion 
(126-128).  LPS-stimulated maturation enhances the ability of antigen (Ag)-loaded DCs to 
activate naïve Ag-specific T cells (126, 127) and blocks CD4+CD25+ regulatory T cell 
inhibition of naïve helper T cells (129).  Although different DC subsets are intrinsically 
capable of inducing different T cell responses, innate stimulation can also influence a 
preferential Th1 versus Th2 response.  E. coli LPS (TLR4), flagellin (TLR5), and CpG DNA 
(TLR9) induce IL-12 in DCs and elicit Th1 responses (130).  However, Pam3cys (TLR2), 
schistosome egg Ags, Candida albicans, and P. gingivalis LPS fail to induce IL-12 in DCs 
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and stimulate Th2 responses (130).  Pam3cys and schistosome egg Ags stimulate sustained 
duration and magnitude of ERK phosphorylation that stabilizes the c-Fos transcription factor, 
which suppresses IL-12 production (130).  DCs indirectly promote B cell antibody secretion 
through the activation of CD4+ T cells that provide the necessary cytokines for B cell 
activation. 
 
B.  DC activation of B cells.  Recently, DCs were shown to directly interact with and 
activate B cells.  DCs interact with B cells through the presentation of intact antigen on their 
surface.  DCs pulsed with antigen in vitro or DCs isolated from mice that have been injected 
with antigen can retain unprocessed antigen, form short-lived clusters with naïve B cells, and 
induce Th2-type antibody responses (131-134).  Antigen endocytosed by FcRIIB can be 
recycled back to the cell surface unprocessed (135).  Follicular DCs present opsonized and 
Ig-complexed antigen through complement and Fc receptors to B cells with high affinity 
BCRs.  This interaction provides survival signals and promotes memory cell differentiation 
in the germinal center (136).  In addition to direct cell contact, DCs secrete soluble factors 
that promote plasma cell differentiation and immunoglobulin (Ig) secretion.  An early study 
showed that CD40-activated DCs secrete IL-12, that promotes plasma cell differentiation of 
naïve B cells, and IL-6, which induces Ig secretion by pre-plasma cells (137).  IFN or CD40-
activated DCs secrete BLyS and APRIL that induce Ig class switching and plasma cell 
differentiation in naïve B cells (138).  TLR-stimulated DCs also secrete BLyS and APRIL 
that promote plasma cell differentiation of MZ and B1 B cells (139).  Viral-stimulated pDCs 
secrete IFN and IL-6 that act on CD40-activated B cells to promote plasmablast formation 
then Ig-secreting plasma cell differentiation (140).  Nucleic acid-containing immune 
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complexes stimulate DCs to secrete proinflammatory cytokines in a TLR-dependent manner 
(141-143).  Thus, DCs can activate B cells by T-independent mechanisms. 
 
C.  Effect of Environment and apoptotic cells on DC and M responses. In addition to 
TLR stimulation, the lymphoid microenvironment is critical in determining the DC response.  
For example, antigen stimulation of DCs alone without a CD40 signal induces T cell 
tolerance (144).  Splenic stromal cells, through contact and secretion of TGF, induce the 
differentiation of a regulatory DC subset.  These DCs secrete IL-10 and nitric oxide that 
inhibit antigen-specific T cell responses promoting tolerance (145, 146).  Exposure to 
necrotic versus apoptotic cells also regulates the DC response.  Necrotic cells activate DCs 
by upregulating cell surface expression of CD86, MHC Class II, and CD40 and induce T cell 
responses, whereas DCs exposed to apoptotic cells do not mature (147, 148).   
DCs and Ms exposed to apoptotic cells are unable to respond to TLR stimulation 
(149) (Sykes and Matsushima, unpublished observations), whereas mer deficient DCs (149) 
and Ms (150) exposed to apoptotic cells respond to TLR signals.  This demonstrates the 
importance of apoptotic cells in regulating innate immunity.  Subsequent experiments 
revealed that signaling through the mer receptor activates PI3K and AKT activity that 
inhibits activation of NF-B and MAP kinases (ERK, JNK, and p38) in response to LPS 
(149).  Therefore, dysregulated innate immune responses due to the inability to appropriately 
respond to and clear apoptotic cells may induce pathological autoimmune responses. 
 
D.  Defects in DCs and Ms associated with lupus. Defects in DCs and Ms have been 
described in lupus.  Monocyte-derived DCs from SLE patients over express CD86 in the 
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absence of any activation signal (151).  Splenic DCs from lupus-prone mice are more 
apoptotic in vivo (152), a significant observation considering that a defect in DC apoptosis 
can independently lead to autoimmunity (153).  In addition, DCs from lupus-prone mice may 
have defects in antigen presentation and stimulatory function in mixed lymphocyte reactions 
(154).  Ms from several autoimmune strains exhibit defects in TLR-stimulated pro-
inflammatory cytokines, including IL-1, IL-6, IL-12, TNF (155-157).  Defective cytokine 
production and increased adhesiveness to extracellular matrix proteins are triggered by 
apoptotic cells (158, 159).  Thus, DC and/or M dysfunction may contribute to lupus 
pathogenesis. 
 
1.7  DC and M-Mediated Tolerance
Previous studies into the mechanisms of B cell tolerance have focused on 
antigen/BCR mediated regulation of autoreactive or chronically antigen-experienced B cells.  
However, the regulation of chronically antigen-experienced B cells during polyclonal 
activation is less understood.  Recently, we described that chronically antigen-experienced B 
cells are regulated by LPS-activated myDCs and Ms, but not T cells, NK cells, NK T cells, 
lyDCs or pDCs, and that repression of Ig secretion is readily reversed upon removal of these 
populations (160).  As few as 1 DC or M could partially repress 100 Sm-specific B cells.  
This potent repressive effect suggested that soluble mediators, in addition to a contact-
mediated mechanism, were involved in the regulation of Ig secretion.  LPS-activated DC and 
M conditioned medium (CM) repressed Sm-specific Ig secretion, confirming that these 
cells secrete soluble factors that regulate Ig secretion.  Neutralization of IL-6 in DC CM 
partially relieved the repressive effect and recombinant IL-6 inhibited LPS induced Ig 
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secretion.  This result was surprising considering the role of IL-6 in promoting plasma cell 
differentiation in naïve B cells.  However, the data showed that only chronically antigen-
experienced, and not naïve B cells, were susceptible to repression by IL-6.  IL-6 repressed 
LPS-stimulated Sm-specific B cells from 2-12H/V8 mice, anti-ssDNA B cells from Ars/A1 
mice, and anti-HEL B cells from HEL-Ig x sHEL mice, whereas B6 and naïve anti-HEL B 
cells were not affected.  The data indicate that autoreactive B cells are regulated beyond 
chronic antigen-induced BCR desensitization, and suggest that chronic antigen stimulation 
reprograms the response to IL-6.  Thus, these findings identified a novel B cell tolerance 
mechanism and a novel role for IL-6 in regulating Ig secretion, and suggested that 
overcoming tolerance in SLE may be associated with defects in the repression of autoreactive 
B cells by myDCs and/or Ms. 
It is important to note that neutralization of IL-6 in DC CM did not completely relieve 
repression and that neutralization of IL-6 in M CM had no effect on the ability of M CM 
to repress Ig secretion (160).  The data suggest that DCs and Ms secrete other repressive 
factors in addition to IL-6.  Subsequent experiments have shown that Ms also secrete a 
soluble form of CD40L (sCD40L) that represses Ig secretion (Kilmon et al, manuscript 
submitted).  Neutralization of sCD40L in IL-6-/- M CM, or in addition to IL-6 
neutralization of B6 M CM, relieves repression of LPS-stimulated Sm-specific B cells.  
Like IL-6, sCD40L only represses chronically antigen-experienced B cells and not naïve B 
cells.  The mechanism of repression by sCD40L does not affect proliferation but inhibits the 
differentiation of B cells to antibody-secreting plasma cells, as sCD40L decreases the percent 
of intracellular IgM cells, the number antibody secreting cells, and Blimp-1 and XBP-1 
transcription important in activating plasma cell differentiation.  Significantly, M-mediated 
23
tolerance is defective in lupus-prone MRL/lpr mice.  Ms and M CM from MRL/lpr mice 
are less efficient than B6 at repressing Sm-specific Ig secretion, coincident with a defect 
secreting repressive soluble factors, IL-6 and sCD40L.  The data suggest that defects in M-
mediated tolerance play a role in autoimmunity. 
Several questions remain in understanding DC and M-mediated tolerance that are 
currently under investigation.  First, IL-6-/- DCs and IL-6-/- x CD40L-/- Ms are capable of 
repressing Ig secretion, suggesting that a third repressive factor exists (Chapter 3).  Secondly, 
we have observed that DCs deficient in TLR4 partially repress LPS-induced Ig secretion 
through a contact-dependent mechanism (Kilmon and Vilen, unpublished observations).  
DCs display nuclear self-antigen on their surface (Carnathan et al, manuscript in 
preparation), possibly interacting with the BCR.  Whether DC surface antigen plays a role in 
B cell tolerance is yet undetermined.  Finally, we have shown that IL-6 and sCD40L repress 
chronically antigen-experienced B cells that are isolated from a nonautoimmune background.  
Thus, a potential defect in lupus is that autoreactive B cells from an autoimmune background 
do not reprogram their responses to IL-6 and sCD40L.  Therefore, it is important to 
determine whether autoreactive B cells from lupus-prone mice are capable of being repressed 
by these soluble factors. 
 
1.8  Model of Tolerance During Innate Immune Responses
During infection, immune cells respond to polyclonal activators, like bacterial and 
viral antigens, through innate immune responses.  Therefore, mechanisms to regulate the 
activation of autoreactive B cells during polyclonal stimulation are necessary to prevent 
autoimmunity.  Blood-born pathogens enter the spleen and peritoneal cavity where they first 
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encounter Ms and B cells.  Marginal zone (MZ) B cells in the spleen and B1 B cells in the 
peritoneal cavity are primed for a quick response to bacterial and viral antigens to fight 
infection as a first line of defense (161).  We propose a model where autoreactive B cells that 
chronically see antigen are repressed by polyclonal activators and maintained in an anergic 
state, while naïve B cells are allowed to mount a response to infectious agents.  We recently 
identified a novel mechanism of tolerance wherein DCs and Ms repress Ig secretion by 
autoreactive B cells (160).  Polyclonal activators stimulate DCs and Ms through TLRs to 
secrete soluble factors that differentially regulate naïve and chronically antigen-experienced 
B cells.  Significantly, IL-6 selectively represses TLR-stimulated autoreactive but not naïve 
B cells.  Thus, we have identified a mechanism that prevents autoimmunity while allowing 
naïve B cells to respond during innate immune responses.  As blood-born pathogens enter the 
spleen and peritoneal cavity and polyclonally activate B cells, autoimmunity could result 
from the lack of secretion of repressive soluble factors by DCs and/or Ms or the inability of 
autoreactive B cells to differentially respond to repressive factors.  Therefore, we hypothesize 
that DC and/or M-mediated tolerance mechanisms are dysfunctional in murine models of 
lupus disease. 
The body of work presented here confirms this hypothesis in part.  DCs and Ms
from lupus-prone mice are defective in repressing autoreactive B cells when stimulated 
through TLR, coincident with a defect in IL-6 and sCD40L secretion (Chapter 2; Kilmon et 
al, manuscript submitted).  We have identified TNF as the final repressive factor secreted 
by DCs and Ms and found that these cells from lupus-prone mice are also defective in 
secreting TNF (Chapter 3).  This could allow TLR-stimulated autoreactive B cells to 
secrete autoantibodies during innate immune responses, promoting autoimmune disease in 
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lupus-prone mice.  The molecular mechanism for the cause of the defects in the repressive 
factors could be key to the etiology of lupus disease (Chapter 4).
 
CHAPTER II 
Dendritic cells from Lupus-Prone Mice are Defective in Repressing Immunoglobulin 
Secretion 
(adapted from the publication by Mileka R. Gilbert, Diane G. Carnathan, Patricia C. 
Cogswell, Li Lin, Albert S. Baldwin, Jr, and Barbara J. Vilen.  2007 Journal of Immunology 
178:5803-5810)
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Abstract 
 
Autoimmunity results from a breakdown in tolerance mechanisms that regulate autoreactive 
lymphocytes.  We recently showed that during innate immune responses, secretion of IL-6 by 
dendritic cells (DCs) maintained autoreactive B cells in an unresponsive state.  Here we 
describe that TLR4-activated DCs from lupus-prone mice are defective in repressing 
autoantibody secretion, coincident with diminished IL-6 secretion.  Reduced secretion of IL-
6 by MRL/lpr DCs reflected diminished synthesis and failure to sustain IL-6 mRNA 
production.  This occurred coincident with lack of NF-B and AP-1 DNA binding and failure 
to sustain IB phosphorylation.  Analysis of individual mice showed that some animals 
partially repressed Ig secretion despite reduced levels of IL-6.  This suggests that in addition 
to IL-6, DCs secrete other soluble factor(s) that regulate autoreactive B cells.  Collectively, 
the data show that MRL/lpr mice are defective in DC/IL-6-mediated tolerance, but that some 
individuals maintain the ability to repress autoantibody secretion by an alternative 
mechanism. 
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Introduction 
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease 
characterized by the production of autoantibodies to nuclear components.  Alternating 
periods of flares and remissions are associated with an increased burden of apoptotic cells, 
the formation of immune complexes, and inflammation (10).  The etiology of SLE remains 
unknown; however, multiple immunoregulatory defects have been identified in lupus-prone 
mice (61, 156, 158, 162-170), including complement deficiencies, TCR signal transduction 
anomalies, and dysfunctional cytokine secretion by macrophages (Ms).  These defects 
contribute to the onset and/or pathogenesis of SLE, while a breakdown in tolerance leads to 
the formation of autoantibodies and immune complexes that may play a role in vasculitis, 
glomerulonephritis, and cerebritis (13). 
Studies in immunoglobulin (Ig) transgenic (Tg) mouse models have defined anergy as
a state of unresponsiveness that regulate autoreactive B cells in the periphery (22, 28, 30, 33,
171). Anergic B cells fail to secrete antibody in response to LPS or antigen immunization
due to receptor unresponsiveness (30, 33, 172). Some anergic B cells exhibit reduced surface
IgM levels (21, 173), decreased lifespan (23, 172), and exclusion from the lymphoid follicle
(23, 46). In the case of B cells specific for the lupus-associated antigen, Smith (Sm), a
partially anergic phenotype is evident. Sm-specific B cells from 2-12H/V8 Ig Tg mice are
unable to secrete Ig in response to LPS, yet maintain surface IgM levels, exhibit a normal
lifespan, and remain competent to enter the B cell follicle (33). Recently, we described that
Sm-specific B cells purified from myeloid dendritic cells (myDCs) and Ms regain the
ability to secrete Ig in response to LPS (160). The data show that secretion of IL-6 by
DC/Ms represses LPS-induced Ig secretion by autoreactive B cells without repressing
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acutely stimulated naïve B cells. This mechanism of tolerance is not limited to Sm-specific
B cells as chronically antigen-experienced HEL- and Ars/A1-specific B cells are similarly
affected (160). These findings identify a unique mechanism of B cell tolerance wherein DCs
and Ms play a central role in regulating autoimmunity during innate immune responses.
MyDCs and plasmacytoid DCs have been described as positive regulators of
immunity promoting growth and differentiation of some B cells through the secretion of IL-
12, IL-6, BLyS, and APRIL (139, 140, 174). Specifically, IL-6 was found to promote plasma
cell survival (175, 176). Although this seems paradoxical, the data indicate that IL-6
differentially regulates naïve and chronically antigen-experienced B cells (160). Studies
identifying IL-6 as a positive regulator focused on B cells from non-Tg mice where the
proportion of autoreactive cells is low. In contrast, the studies showing that IL-6 represses
autoantibody production used self-reactive Ig Tg models where the B cells were constantly
exposed to self-antigen (160). Thus, IL-6 acts as a positive or negative regulator of B cells
depending on the history of BCR ligation. We propose that chronic BCR ligation by self-
antigen reprograms IL-6R-mediated outcomes allowing naïve B cells to produce Ig in 
response to polyclonal stimulation while simultaneously repressing autoreactive B cells from 
producing autoantibody.  These findings identify a novel B cell tolerance mechanism, and
suggest that overcoming tolerance in SLE might be associated with defects in the repression
of autoreactive B cells by myDCs and/or Ms.
In this report, we show that LPS-activated DCs from MRL/lpr mice inefficiently 
repress Sm-specific Ig secretion, coincident with diminished IL-6 secretion. Mechanistically, 
diminished secretion of IL-6 resulted from decreased synthesis of IL-6 mRNA coincident 
with decreased IB phosphorylation and reduced DNA binding by NF-B and AP-1. These 
data identify signal transduction defects in DCs that occur coincident with diminished IL-6 
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secretion and failure to repress Ig secretion by autoreactive B cells. Further analysis of DC-
mediated tolerance mechanisms revealed that DC conditioned medium (CM) from some 
MRL/lpr mice repressed Ig secretion despite low levels of IL-6. This suggested that 
additional soluble factors are involved in repressing autoantibody secretion. These findings 
implicate DC defects in the breakdown of tolerance in lupus-prone mice and suggest that 
defects in multiple factors may be required for the complete breakdown of tolerance 
associated with autoimmunity.  
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Materials and Methods 
Mice 
2-12H/V8/C-/- immunoglobulin transgenic mice were previously described (33, 160). 
MRL/MpJ-Faslpr/J (MRL/lpr) and C57BL/6J (B6) mice were purchased from The Jackson 
Laboratory, and NZM2410 mice from Taconic.  NZBxNZWF1 mice were obtained from 
Trine Jorgensen (University of Colorado), MRL/MpJ (MRL) and B6.Faslpr (B6.lpr) from 
Stephen Clarke (University of North Carolina).  2-12H/V8/C-/- mice were used at 9-17 
weeks of age.  All other mice were used at 6-10 weeks old.  All studies were approved by the 
Institutional Animal Care and Use Committee. 
 
Reagents and Antibodies 
7-AAD, rIL-6, and antibodies to CD11c, CD11b, B220, and IL-6 were purchased from BD 
Biosciences, GR1 and TLR4 from eBiosciences, phospho-IB from Cell Signaling, IB
and -tubulin from Santa Cruz, and IgG HRP from Promega. Streptavidin-AP was purchased 
from Southern Biotech, anti-actin, TEPC 183, and Escherichia coli 055:B5 LPS from Sigma 
Aldrich, 5,6-Dichlorobenzimidazole 1--D-ribofuranoside (DRB) from Calbiochem, E. coli 
0111:B4 LPS from List Biological Laboratories, mouse GM-CSF and IL-4 from PeproTech, 
poly (I:C) and R848 from InvivoGen, and CpG oligodeoxynucleotides (ODN) and non-CpG 
ODN from Coley Pharmaceutical Group. JA12.5, 54.1, 187.1, HB100, and CRL 1969 were 
purified from hybridoma culture supernatant. 
 
Cell Purification 
32
B cells were purified from 2-12H/V8/C-/- spleens by negative selection (StemCell 
Technologies) (160).  Biotinylated CD3 antibody was added to the antibody cocktail to 
increase the efficiency of T cell depletion. B cells were 86-93% pure with <3% T cells and 
<7% DCs/Ms.  Splenic CD11c+ cells (~70% pure) were purified by positive selection 
(Miltenyi Biotec) and found to contain 20% lymphocytes and 10% Ms. 
 
Bone marrow-derived DC (BMDC) Cultures 
Bone marrow-derived DCs were generated as previously described (160).  BMDCs were 
>95% CD11c+ (CRL 1969 hybridoma).  Conditioned medium (CM) was made from 1x104
BMDCs (0.2 ml) cultured for an additional 4 days with or without Sigma LPS (30 µg/ml).  
5x105 BMDCs (0.2 ml) were cultured for an additional 4 days with or without poly (I:C) (50 
µg/ml), R848 (10 µg/ml), CpG ODN (1 µg/ml), or non-CpG ODN (1 µg/ml).  In experiments 
where RNA was isolated or nuclear extracts were prepared, BMDCs were stimulated with E. 
coli 0111:B4 LPS (List Biological Laboratories) that was re-purified (177) and confirmed to 
be unable to induce IL-6 secretion by TLR4-/- DCs. 
 
B cell Cultures 
Splenocytes containing 1x105 B cells, or the equivalent number of purified B cells, were 
cultured with Sigma LPS (30 µg/ml) for 4 days.  In the mixed B cell experiments, purified 
B6 (5x104; IgMb) and 2-12H/V8 (5x104; IgMa) B cells were cocultured with LPS for 4 days 
as above.  BMDCs, CD11c+ splenocytes, or BMDC CM (25% of final volume) were added 
to B cell cultures on day 0.  The IL-6 in DC CM was neutralized with either anti-IL-6 
antibody or a control rat IgG1 antibody (54.1). 
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ELISA 
IgMa/ (encoded by 2-12H/V8/C-/-) was captured with anti- (187.1), detected with 
biotinylated anti-IgMa (HB100) and Streptavidin-AP as previously described (33).  Purified 
mouse IgMa/ (TEPC 183) served as the standard control. IgMa/ levels were plotted as 
“percent of control” defined by the level of Ig secretion in LPS-stimulated cultures of 
purified 2-12H/V8/C-/- B cells (100%).  IL-6 was quantitated by capturing with anti-IL-6 
(clone MP5-20F3) and detecting with biotinylated anti-IL-6 (clone MP5-32C11) and 
Streptavidin-AP.  Recombinant IL-6 served as the standard control.  
 
Real time (RT)-PCR  
RNA was prepared from BMDCs treated with re-purified LPS (15 µg/ml) by solubilization in 
Trizol (Invitrogen) and treatment with Turbo DNase (Ambion).  Reverse transcription with 
oligo(dT) primers was performed with Superscript II (Invitrogen).  The amount of IL-6 
message was determined using the TaqMan Assay-On-Demand primer-probe sets (Applied 
Biosystems) and the ABI 7000 sequence detection system.  IL-6 mRNA transcript levels 
were normalized to the amount of 18S ribosomal RNA transcription according to the 
following equation: %18S = 2^ [-(IL-6 – 18S units)].  To measure IL-6 mRNA stability, 
BMDCs were stimulated with re-purified LPS (15µg/ml) for 6 hrs and then treated with 50 
µM DRB for 15, 30, and 60 min to block transcription.  mRNA was quantitated by RT-PCR 
as described above. 
 
Electrophoretic Mobility Shift Assay (EMSA)  
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BMDCs were stimulated with re-purified LPS (15 µg/ml) and gel shift assays were 
performed as previously described (178). 
 
Statistical Analysis 
Exact Wilcoxon rank sum test was used for most unpaired two-sample comparisons. When 
total sample size was small (<8), t test was used instead. For test differences between paired 
observations, exact Wilcoxon signed rank test was used. p values < 0.05 were considered 
significant and denoted by *.  
 
35
Results  
The frequencies of splenic myDCs and Ms are not diminished in MRL/lpr mice. 
Maintaining B cell tolerance during activation of the innate immune system is crucial in 
preventing autoimmunity. We have previously shown that stimulation through TLR4 
activates myDCs and Ms to secrete soluble factors thereby repressing Ig secretion by 
chronically antigen-experienced (autoreactive) B cells (160).  To determine if the breakdown 
of tolerance in lupus-prone mice was associated with the lack of a repressive cell type, we 
compared the frequency of splenic M and DC subsets in MRL/lpr and B6 mice.  As shown 
in Figure 2.1 and Table 2.1, the frequencies of myDCs (CD11chi/CD11bint/hi) and 
plasmacytoid DCs (pDCs, CD11clo/CD11b-/B220+/GR1+) were not significantly different.  
The lymphoid DCs (lyDCs, CD11clo/CD11b-/B220-/GR1-) were significantly decreased in 
MRL/lpr, however this population is not involved in DC/M-mediated tolerance (160).  The 
CD11c-/CD11bhi and CD11c-/CD11blo populations were increased in MRL/lpr mice, raising 
the possibility that these populations might secrete an activator that enhances Ig secretion.  
However, when isolated by cell sorting, these populations did not augment LPS-induced Ig 
secretion or affect the ability of B6 DCs to regulate Ig secretion by Sm-specific B cells (data 
not shown), suggesting that neither population promotes the loss of B cell tolerance.  Thus, 
neither diminished frequency of myDCs and Ms nor secretion of an activator accounts for 
the loss of tolerance in MRL/lpr mice. 
 
DCs from MRL/lpr mice fail to efficiently repress Sm-specific B cells.  
LPS-activated DCs from B6 mice regulate chronically antigen-experienced B cells (160).  To 
assess if DCs from MRL/lpr mice were capable of repressing Ig secretion, we cocultured 
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Sm-specific B cells with bone marrow-derived DCs (BMDCs) from B6 or MRL/lpr mice 
(Figure 2.2A).  Compared to B6 DCs, MRL/lpr DCs were less efficient at repressing Sm-
specific B cells when cultured at B cell: DC ratios of 10:1, 20:1, and 100:1 (p = 0.016, 0.004,
and 0.015 respectively).  These differences were not due to contaminating cells, because 
BMDCs from B6 and MRL/lpr mice contained >95% myDCs, and sorted B cells compared 
to negatively selected B cells from 2-12H/V8 mice cultured with DCs from MRL/lpr mice 
exhibited similar results (data not shown).  To determine if splenic DCs were also defective 
in repressing autoreactive B cells, splenic CD11c+ cells were isolated from B6 and MRL/lpr 
mice, and cocultured with B cells from 2-12H/V8 mice (B cell: DC ratio 10:1).  As shown 
in Figure 2.2B, ex vivo B6 DCs repressed significantly better than DCs purified from 
MRL/lpr mice (p = 0.015), indicating that the defect was not specific to BMDCs.  
Collectively, the data indicate that myDCs from MRL/lpr mice are present at a normal 
frequency, but they are defective in repressing Ig secretion by autoreactive B cells. 
 
DCs from MRL/lpr mice are defective in IL-6 secretion 
We previously showed that IL-6 secreted by DCs repressed autoreactive B cells (160).  To 
determine if diminished IL-6 was associated with the inability of MRL/lpr DCs to repress 
Sm-specific Ig secretion, we measured IL-6 secretion. LPS-activated BMDCs (Figure 2.3A) 
and splenic CD11c+ cells (Figure 2.3B) from MRL/lpr mice secreted significantly less IL-6 
compared to B6 controls (p < 0.001 and p = 0.003 respectively).  To assess if this defect was 
unique to MRL/lpr mice, we quantitated LPS-induced IL-6 secretion from BMDCs from 
several other lupus-prone models.  As shown in Figure 2.3A, BMDCs from MRL, 
NZM2410, and NZBxNZWF1 were defective in secreting IL-6 when compared to B6 (p <
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0.0001, p < 0.0001, and p = 0.002 respectively).  Interestingly, B6.lpr mice were not 
defective in secreting IL-6 (p = 0.932), suggesting that the inability to secrete IL-6 is 
associated with the MRL background.  Defective IL-6 production was not secondary to IL-10 
inhibiting TLR signaling, as MRL/lpr DCs secreted decreased levels of IL-10 and 
neutralizing IL-10 did not restore IL-6 levels (data not shown).  To determine whether 
defective IL-6 secretion was limited to stimulation through TLR4, we measured IL-6 
secretion from MRL/lpr-derived DCs in response to other TLR ligands.  As shown in Figures 
2.3C-E, IL-6 secretion was increased when MRL/lpr BMDCs were stimulated through TLR3 
(poly (I:C), p = 0.006); however, secretion was defective when stimulated through TLR7 
(R848, p = 0.028) and TLR9 (CpG ODN, p = 0.016).  This indicates that not all TLRs are 
affected by this defect, and that mutation within the IL-6 structural gene is unlikely to explain 
the reduced levels of IL-6.  Collectively, the data indicate that DCs from multiple strains of 
autoimmune mice exhibit defects in cytokine secretion induced through some TLRs. 
 
Diminished IL-6 secretion is not due to decreased TLR4 expression or survival. 
Expression of TLRs ensures that DCs are activated during innate immune responses. It was 
possible that the decreased secretion of IL-6 from MRL/lpr DCs reflected a reduced 
expression of surface TLR4.  As shown in Figure 2.4A, the expression of TLR4 on myDCs 
from B6 (MFI 58.9 + 12.6) and MRL/lpr (MFI 68.1 + 10.9) mice was not significantly 
different.  Likewise, BMDCs from B6 and MRL/lpr mice did not differ in TLR4 expression 
(data not shown), nor did they differ in viability as determined by 7-AAD staining at day 4 
(Figure 2.4B).  Thus, diminished surface expression of TLR4 or decreased survival do not 
account for the decreased IL-6 secretion by LPS-activated DCs from MRL/lpr mice.  
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Defective IL-6 secretion is associated with failure to sustain IL-6 transcription.
Transcriptional regulation of IL-6 depends on several signal transduction pathways that 
activate multiple transcriptional regulators including NF-B and AP-1.  To determine if the 
diminished secretion of IL-6 by MRL/lpr DCs was due to defective transcriptional 
regulation, we LPS-stimulated BMDCs from B6 and MRL/lpr mice and quantitated IL-6 
mRNA levels by real time (RT)-PCR.  The basal level of IL-6 mRNA in the MRL/lpr mice 
was slightly lower than in B6 mice (Figure 2.5A).  Upon stimulation with LPS, IL-6 mRNA 
levels in B6 and MRL/lpr DCs were dramatically increased; however, the magnitude of the 
response by MRL/lpr BMDCs was 7-fold lower.  Further, the sustained levels of IL-6 mRNA 
production were higher in B6 compared to MRL/lpr mice (24 hr and 96 hr timepoints).  To 
determine if decreased mRNA stability contributed to the decreased production of IL-6 
message, BMDCs were LPS-stimulated for 6 hours followed by pharmacological attenuation 
of transcription.  The levels of IL-6 mRNA in BMDCs from B6 and MRL/lpr mice were 
quantitated by RT-PCR.  As shown in Figure 2.5B, the rates of mRNA degradation in the 
MRL/lpr DCs did not change over time; however, the IL-6 mRNA levels in B6 DCs were 
reduced by 3-fold within 15 minutes of attenuating new transcription.  This indicates that IL-
6 message is inherently unstable and that sustained production of IL-6 mRNA requires 
continual synthesis.  Further, given that degradation was not observed in DCs from MRL/lpr 
mice, the data indicate that increased degradation does not contribute to the diminished IL-6 
mRNA levels.  This suggests that MRL/lpr DCs harbor a defect at or upstream of 
transcriptional initiation that reduces the level of IL-6 mRNA and protein.  
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To assess if decreased IL-6 mRNA levels were associated with defects in NF-B or
AP-1 activation, we compared the DNA binding activity in nuclear extracts prepared from 
B6 and MRL/lpr DCs.  The DNA binding activity of NF-B from LPS-stimulated B6 DCs 
occurred within 10 minutes, with robust binding at 6 hours.  In contrast, the DNA binding 
activity of NF-B from MRL/lpr DCs was diminished at these same timepoints (Figure 
2.6A).  This was not a reflection of unequal protein loading, as the levels of an unrelated 
nuclear protein (PCNA) were comparable.  The specificity of NF-B for the DNA probe was 
confirmed by diminished complex formation in the presence of unlabelled probe (competitor 
DNA), and failure of a mutant competitor DNA (mutant DNA) to reduce complex formation 
(Figure 2.6B).  To identify the NF-B subunits involved in DNA binding, we supershifted 
the DNA/protein complex with subunit-specific antibodies.  As shown in Figure 2.6C, p65 
and c-Rel, but not p50, were identified as components of the NF-B complex formed in B6 
DCs following 6 hour LPS stimulation.  p65 and c-Rel anti-sera were specific for these 
components as pre-immune serum failed to supershift a protein/DNA complex (data not 
shown).  Similar to NF-B, DNA binding by AP-1 was also markedly diminished in DCs 
from MRL/lpr compared to B6 mice (Figure 2.6D).  Thus, LPS-stimulated MRL/lpr DCs fail 
to activate key transcriptional regulators required for IL-6 gene transcription.  
Nuclear translocation of NF-B is dependent on phosphorylation and degradation of 
IB (179).  To assess if the lack of NF-B DNA binding was associated with defects in IB
phosphorylation/degradation, we immunoblotted whole cell lysates from LPS-stimulated B6 
and MRL/lpr BMDCs.  B6 DCs showed induced phosphorylation of IB at 5 minutes that 
was sustained through 6 hours (Figure 2.7A, left panel).  In contrast, MRL/lpr DCs induced 
IB phosphorylation at 5 minutes with maximal phosphorylation at 15 minutes.  
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Phosphorylation was not evident at 45 minutes or 6 hours (Figure 2.7A, right panel).  
Similarly, IB degradation was delayed following LPS stimulation of MRL/lpr DCs, 
indicating that defects in TLR4-induced signal transduction correlate with lack of IL-6 
mRNA production and protein secretion.  To assess if other TLR pathways in MRL/lpr DCs 
were similarly affected, we assessed IB phosphorylation in response to TLR3 ligation.  
We showed in Figure 2.3 that despite defects in TLR4-, TLR7- and TLR9-induced IL-6 
production, TLR3-induced IL-6 production was enhanced.  This revealed that the defect in 
IL-6 production by MRL/lpr DCs did not affect all TLRs.  To correlate TLR-induced protein 
secretion with TLR-mediated signal transduction, we assessed IB phosphorylation in 
response to poly (I:C).  As shown in Figure 2.7B, poly (I:C)-induced IB phosphorylation 
was comparable between DCs derived from B6 and MRL/lpr mice.  Collectively, the data 
suggest failure to sustain IB phosphorylation reduces NF-B activation, diminishes IL-6 
transcription, and ultimately decreases IL-6 protein synthesis by MRL/lpr DCs.  This 
supports the idea that continuous TLR4 signal transduction is required to maintain IL-6 
secretion and suggest this is defective in DCs from lupus-prone mice (180). 
 
Autoantibody secretion is repressed by IL-6 and other soluble factors. 
We have previously shown that IL-6 repressed 75% of Ig secretion by Sm-specific B cells.  
Here, we show that DCs from lupus-prone MRL/lpr mice exhibit markedly decreased IL-6 
levels coincident with their inability to regulate Ig secretion.  To determine the importance of 
decreased IL-6 in the breakdown of tolerance, we assessed the ability of conditioned medium 
(CM) from B6 and MRL/lpr DCs to repress Ig secretion.  CM allowed us to distinguish the 
effects of soluble mediators from the effects of cell contact.  As shown in Figure 2.8A, DC 
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CM from most B6 mice repressed 70-90% of Ig secretion.  In contrast, the ability of DC CM 
from individual MRL/lpr mice to repress Ig secretion was extremely variable (10-90% 
repression, p= 0.004).  Given the central role for IL-6 in repressing autoantibody secretion 
(160), we reasoned that if IL-6 were the sole repressive factor, there would be a direct 
correlation between IL-6 in DC CM and Ig secretion.  However, this broad range of 
repression only partially correlated with IL-6 levels (data not shown).  Despite the fact that 
all MRL/lpr mice exhibited low levels of IL-6, four individuals still repressed 80-90% of Ig 
secretion (Figure 2.8A).  To assess if the low levels of IL-6 secreted by MRL/lpr mice 
contributed to Ig repression, we neutralized any remaining IL-6 in the DC CM of mice 
retaining repressive function, then assessed the ability of the CM to regulate Ig secretion. As 
shown in Figure 2.8B, neutralization partially restored Ig secretion (p = 0.031), confirming 
that that the low levels of IL-6 regulated Ig secretion.  Interestingly, secretion comparable to 
controls (100%) was never attained, suggesting that in addition to IL-6, other DC-derived 
soluble mediators regulate Ig secretion.  It was possible that the variability in repression by 
MRL/lpr DC CM was due to the secretion of an activating factor by the MRL/lpr DCs.  We 
addressed this in two ways.  First, we added recombinant IL-6 (rIL-6) to the MRL/lpr DC 
CM, and then assessed Ig secretion by Sm-specific B cells.  When added to the CM from 
three individual mice, rIL-6 repressed Ig secretion indicating that if activating factors were 
present, they did not override the repressive effect of IL-6 (data not shown).  In a second 
experiment, we assessed if MRL/lpr DCs secreted an activator by determining if MRL/lpr 
DC CM activated naïve B6 B cells.  We previously showed that DC CM did not repress 
naïve B cells (160); thus, the presence of an activator may be more evident when Ig secretion 
is not simultaneously being repressed by the low levels of IL-6 in the MRL/lpr DC CM.  The 
42
data indicate that MRL/lpr DC CM did not increase Ig secretion of naïve B6 B cells, 
indicating that the dysregulated production of an activator is unlikely (data not shown).  
Collectively, the data indicate that during innate immune responses, IL-6 and another 
repressive factor(s) regulates B cells chronically exposed to antigen.  Further, this mechanism 
appears defective in lupus-prone mice coincident with diminished secretion of IL-6.  
However, it remained unclear if soluble factors secreted by LPS-activated DCs repressed 
autoreactive B cells when present in mixed populations with naïve cells.  To assess this, we 
cocultured naïve (B6) and autoreactive (2-12H/V8) B cells with DC CM prepared from B6 
and MRL/lpr DCs.  As shown in Figure 2.8C, DC CM prepared from B6 cells, but not 
MRL/lpr cells, repressed Ig secretion in the mixed B cell cultures (p = 0.009) (Figure 2.8C).  
The data suggest that DC-mediated repression regulates mixed populations of autoreactive 
and naïve B cells.
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Discussion 
The defects leading to the breakdown in B cell tolerance remain a central focus in 
understanding SLE.  Previous studies showed that during innate immunity Sm-specific B 
cells were regulated by myDCs and Ms through the secretion of soluble mediators (160).  
We propose a model where polyclonal activators stimulate myDCs and Ms to secrete IL-6, 
which selectively represses autoreactive B cells, while naïve B cells mount a polyclonal 
antibody response to bacterial and viral antigens.  In this report, we show that DCs from 
lupus-prone mice are less efficient at repressing autoreactive B cells coincident with a defect 
in secreting IL-6.  This DC defect was not due to decreased survival or TLR4 expression, 
lack of a regulatory DC subpopulation, or the secretion of factors that enhance Ig secretion.  
Instead, the reduced IL-6 secretion resulted from the inability of MRL/lpr DCs to induce or 
maintain IL-6 transcription in response to LPS.  Analysis of upstream signaling effectors 
showed that, although LPS induced IB phosphorylation, it was not sustained.  Further, 
DNA binding by NF-B and AP-1 were markedly decreased.  These findings indicate that 
MRL/lpr DCs exhibit a TLR4 signal transduction defect at, or upstream of, IB kinase 
(IKK)/IB/NF-B activation that results in diminished IL-6 mRNA production and protein 
secretion.  
Previous data showed that rIL-6 effectively regulated chronically antigen-experienced 
B cells (160).  At several B cell: DC ratios, MRL/lpr DCs were less efficient at repressing Ig 
secretion compared to B6 DCs.  However, despite significant defects in IL-6 secretion, they 
still repressed 53% of anti-Sm secretion at a ratio of 100:1 (Figure 2.2A).  Further, DC CM 
was less efficient at repressing Ig secretion compared to intact DCs indicating that a contact-
dependent mechanism might partially regulate Ig secretion.  In support of this, we have 
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observed that DCs deficient in TLR4 partially repressed LPS-induced Ig secretion; however, 
repression was lost when the cells were separated in a transwell apparatus (Kilmon and 
Vilen, unpublished observations). 
The finding that repression of Ig secretion by DCs is multifaceted fits well with the 
heterogeneity of human disease.  We propose that defects in any regulatory component may 
predispose to autoimmunity, but complete loss of tolerance requires multiple defects.  Our 
data show that the repressive ability of LPS-activated MRL/lpr DCs was variable.  Some 
DCs efficiently repressed Ig secretion, despite diminished IL-6 production (Figure 2.2, 
2.3A/B, 2.8A), while others failed to repress secretion coincident with reduced IL-6 levels.  
Compared to the contact-dependent mechanism described above, this repressive activity was 
apparent in the CM from some MRL/lpr mice, indicating that DCs secrete additional 
repressive factors that contribute to the regulation of Ig secretion.  Thus, despite markedly 
decreased IL-6 secretion by DCs from all mice analyzed, some likely harbor defects in 
another repressive factor(s) making them more susceptible to autoimmunity during innate 
stimulation.  Although a direct correlation between Ig secretion and IL-6 levels in MRL/lpr 
mice was not evident, we favor the interpretation that IL-6 and another repressive factor 
regulates Ig secretion because IL-6 deficient DCs repress LPS-induced Ig secretion 
(unpublished observations) and neutralizing IL-6 only partially restored Ig secretion (Figure 
2.8B).  This indicates that the low levels of IL-6 secreted by MRL/lpr DCs partially represses 
Ig secretion, but that IL-6 is not the sole means of regulating autoimmunity during innate 
immune responses. 
The inability of LPS-stimulated MRL/lpr DCs to produce IL-6 and efficiently repress 
Ig secretion suggests that defects in innate immune responses contribute to autoimmunity.  
45
Our data show that DCs derived from MRL/lpr mice are unable to sustain IB
phosphorylation, thereby reducing NF-B DNA binding and IL-6 mRNA synthesis.  This 
suggests an intrinsic defect where lack of sustained TLR-mediated signal transduction leads 
to decreased IL-6 protein secretion.  This could reflect a defect in the TLR signaling pathway 
or possibly the selective formation of NF-B complexes that are less transcriptionally active.  
Aberrant cytokine production and abnormal NF-B activity in T cells and Ms from lupus-
prone mice and lupus patients have been associated with decreased p65, increased p50 
homodimers which are more inhibitory to gene transcription, reduced binding of p50/c-Rel 
and p65 NF-B complexes, and increased activity of histone deacetylases (181, 182).  
Unfortunately we could not identify the NF-B subunits formed by MRL/lpr DCs because 
DNA binding was not observed at levels sufficient for supershifting. 
MyD88-dependent, TLR-induced activation of NF-B and AP-1 is mediated through 
TRAF6 (183).  Thus, the findings that both NF-B and AP-1 DNA binding activity are 
reduced (Figure 2.6), and that IL-6 secretion and IB phosphorylation are defective only 
upon stimulation through MyD88-dependent TLRs (TLR4, 7, and 9, but not TLR3), suggest 
a defect in the MyD88-dependent signaling pathway possibly at or upstream of TRAF6.  
Alternatively, a defect at the level of the TLR4 receptor may occur.  Yang et al showed that 
persistant TLR4 signals are required for normal DC secretion of IL-6 (180). W In the case of 
dysfunctional MRL/lpr DCs, the TLR4 receptor may become desensitized to LPS following 
an initial stimulus, mimicking LPS removal and causing the decreased phospho-IB and 
IL-6 mRNA levels seen at later timepoints (Figures 2.5 and 2.7).  In addition, exposure to 
apoptotic cells may affect the TLR4 response.  Apoptotic cells fail to induce inflammatory 
responses, in part by repressing DC activation (147).  Thus, the increased burden of apoptotic 
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cells associated with SLE may dysregulate some of the TLRs, rendering them incapable of 
secreting cytokines that are needed to repress autoantibody secretion.  In support of this, 
others have shown that apoptotic cells cause defective IL-6 secretion by macrophages (158), 
and mice functionally deficient in the phagocytosis of apoptotic cells get a lupus-like disease 
(61).  
Increased production of pro-inflammatory cytokines such as IL-6, contribute to the 
inflammatory response and pathogenesis of lupus nephritis (184, 185).  SLE patients (186-
189) and diseased, lupus-prone mice (190-192) exhibit elevated serum IL-6 levels (2-19 
pg/ml), yet fail to repress Ig secretion.  Although elevated, this level of systemic IL-6 is 
insufficient to repress autoreactive B cells in vitro (160).  Therefore, we propose that 
colocalization of DCs and B cells is necessary to provide sufficient IL-6 to repress Ig 
secretion.  Our findings showed that DCs derived from MRL/lpr mice secrete reduced levels 
of IL-6, coincident with lack of Ig repression.  We propose that once tolerance is overcome, 
autoantibody secretion and immune complex formation induce systemic production of pro-
inflammatory mediators, promoting inflammation and pathogenesis.  Consistent with this 
model, CpG-stimulated dendritic cells from SLE patients produced lower levels of IL-6 
(193), while endothelial cells (194-196), mesangial cells in the kidney (197, 198), and 
infiltrating monocytes/macrophages (199) secrete elevated levels of IL-6.  This suggests that 
IL-6 plays a beneficial role when released in a local microenvironment between myDCs and 
autoreactive B cells, yet when elevated systemically, it induces inflammation, tissue 
destruction, and spontaneous Ig production by activated B cells (186, 200-202).  Therapies 
aimed at neutralizing the inflammatory effects of IL-6 may have short-term benefits in 
47
treating lupus nephritis, however, they are likely to promote loss of tolerance in newly 
emerging B cells during innate immune activation. 
Immunoglobulin secretion by B cells is induced by ligation of the TLR and/or BCR. 
BCR-induced Ig secretion is regulated by lack of T cell help and sustained BCR-induced 
calcium signaling and prolonged Erk activation (40, 172, 203, 204).  In contrast, TLR-
induced Ig secretion is regulated by soluble factors secreted from DCs and Ms (160).
Although the mechanisms regulating the BCR and TLR are unique, signals derived from 
chronic BCR stimulation impact TLR-induced activation.  For example, the chronic Erk 
activation associated with continuous exposure to self-antigens represses TLR9-induced Ig 
secretion, whereas, acute Erk activation following BCR stimulation of naïve B cells promotes 
TLR9-induced Ig secretion (45, 83).   Similarly, chronic BCR exposure to self-antigen 
reprograms IL-6R signal transduction to repress Ig secretion (160).  However, B cells that 
have been acutely stimulated and exposed to IFN-/ induce Ig secretion in response to IL-6 
(140).  Our data expand our understanding of IL-6 to include a role in repressing Ig secretion 
by autoreactive B cells.  During autoimmunity, the tolerance mechanisms that regulate 
autoreactive B cells become dysregulated.  For many B cells with autoreactive specificities, it 
remains unclear if BCR and/or TLR responses facilitate autoantibody production.  Our 
studies of TLR-mediated responses in Sm-, HEL- and Ars/A1-specific autoreactive B cells 
identify DCs and Ms as key regulatory cells during innate immune responses, and show 
that DC-mediated tolerance is defective in lupus-prone MRL/lpr mice.  These findings 
implicate dysregulated innate immune responses in the autoantibody production associated 
with SLE.  
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Figure 2.1.  The distribution of splenic myDCs and Ms are comparable between B6 
and MRL/lpr mice.  DC and M subsets were separated based on CD11c and CD11b 
expression.  Dot plots are representative of nine mice each. 
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Figure 2.2.  DCs from MRL/lpr mice fail to efficiently repress Sm-specific Ig secretion. 
LPS-stimulated (30 µg/ml) splenocytes (1x105 B cells) or purified B cells (1x105) were 
cocultured with the indicated ratios of BMDCs (A), or ex vivo splenic DCs (B).  Secreted 
IgMa/ levels were quantitated by ELISA from the day 4 culture supernatant.  LPS-
stimulated purified B cells (100%) secreted 1-10 µg/ml IgMa/. Data represent 14 (A) and 8 
(B) MRL/lpr mice. (Controls,  B6, MRL/lpr). 
 
52
Figure 2.3.  DCs from MRL/lpr mice are defective in IL-6 secretion upon TLR4, 7 and 9 
stimulation, but not upon TLR3 stimulation. 1x104 BMDCs (A), or 1x105 ex vivo splenic 
DCs (B), were stimulated with LPS (30 µg/ml).  5x105 BMDCs were stimulated with poly 
(I:C) (50 µg/ml) (C), R848 (10 µg/ml) (D), and non-CpG ODN (/) or CpG ODN ( /
)(1µg/ml) (E).  IL-6 was quantitated by ELISA from the day 4 culture supernatants.  Data 
represent at least 5 mice per group.  ( B6, MRL/lpr,XMRL, B6.lpr, NZM2410, 
NZBxNZWF1)
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Figure 2.4.  MyDCs from B6 and MRL/lpr mice have similar levels of TLR4 surface 
expression and no difference in survival. MyDCs within the CD11c+ splenocyte 
population were gated as CD11chi/CD11bint/hi, and then analyzed for TLR4 expression (A).  
LPS-stimulated BMDCs were stained with 7-AAD on Day 4 (B).  The thick black line 
represents B6 mice.  The thin gray line represents MRL/lpr mice.  Histogram shows a 
representative plot from three experiments. 
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Figure 2.5.  DCs from MRL/lpr mice show a decrease in synthesis and ability to sustain 
IL-6 mRNA levels. Real time-PCR was performed on RNA isolated from LPS stimulated 
BMDCs (A) untreated or (B) treated with DRB at the indicated timepoints.  The data from 
three individual B6 () and six MRL/lpr () mice are plotted as %18S. 
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Figure 2.6.  DCs from MRL/lpr mice fail to activate NF-B and AP-1. BMDCs were 
stimulated with LPS (15 µg/ml) for the indicated times.  Nuclear extracts were prepared, and 
NF-B/DNA binding (A) or AP-1/DNA binding (D) was assessed by EMSA.  Nuclear 
extracts prepared from unstimulated B6 BMDCs (lane 1) or from DCs stimulated 6 hours 
with LPS (lanes 2-4) were incubated with radiolabeled DNA probe (lanes 1-4), unlabeled 
competitive DNA (lane 3), or mutant DNA (lane 4), and NF-B DNA binding was assessed 
by EMSA (B).  NF-B/DNA complexes in the nuclear extracts from unstimulated B6 DCs 
(lane 1) or from DCs stimulated 6 hours with LPS (lane 2-5) were supershifted using p65 
(lane 3), p50 (lane 4), or c-Rel antiserum (lane 5) (C). 
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Figure 2.7. TLR4-stimulated DCs from MRL/lpr mice are unable to sustain IB
phosphorylation. BMDCs (2x106) from B6 and MRL/lpr mice were stimulated with LPS 
(15 µg/ml) (A) or poly (I:C) (50 µg/ml) (B) for the indicated timepoints.  Phospho-IB,
IB, and  tubulin (A) or actin (B) expression in whole cell lysates was determined by 
immunoblotting. Data represent 7 (A) and 3 (B) experiments. 
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Figure 2.8.  In addition to IL-6, other soluble factors regulate autoantibody secretion. 
Purified B cells (1x105) from 2-12H/V8 mice were stimulated with LPS (30 µg/ml) in the 
absence () or presence of DC CM (25% of final volume) from B6 () or MRL/lpr ()
mice (A).  DC CM from individual MRL/lpr mice () was untreated or neutralized with 
anti-IL-6 antibody (50 µg/ml) prior to coculture with B cells from 2-12H/V8 mice (B).  
5x104 purified B cells from 2-12H/V8 and B6 mice were stimulated with LPS (30 µg/ml) in 
the absence () or presence of DC CM from B6 () or MRL/lpr () mice (C).  Secreted 
IgMa/ levels were quantitated by ELISA from the day 4 culture supernatant.  LPS-
stimulated purified B cells (100%) secreted 1-10 µg/ml IgMa/. Data represent 15 (A), 5 (B), 
and 4 (C) MRL/lpr mice.
 
CHAPTER III 
Dendritic Cells and Macrophages Secrete TNF that Regulates Smith Antigen-Specific 
B cells During Innate Immune Responses
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Abstract 
In the absence of B cell tolerance, polyclonal activation of B cells induces autoimmunity. 
Recently, we described that autoreactive B cells are regulated during innate immune 
responses by myeloid dendritic cells (myDCs) and macrophages (Ms) through their 
secretion of IL-6 and soluble CD40L (sCD40L).  DC/M-mediated tolerance is unique in 
that immunoglobulin (Ig) secretion is repressed in B cells that are chronically exposed to 
antigen but not in naïve B cells.  Analysis of DC/M-mediated tolerance in murine models 
of SLE showed that DCs and Ms from lupus-prone mice are defective in repressing 
autoreactive B cells, coincident with defects in IL-6 and sCD40L secretion.  In this report, we 
identify TNF as the final repressive factor secreted by TLR-activated DCs and Ms.  
TNF selectively repressed Smith (Sm)-specific B cells.  Like IL-6 and sCD40L, DCs and 
Ms from lupus-prone MRL/lpr mice were defective in secreting TNF. Our data define a 
tolerogenic role for TNF and suggest that defects in DC and M-mediated tolerance 
contribute to autoimmunity during innate immune responses. 
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Introduction 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the 
production of autoantibodies that bind nuclear self-antigens.  Autoimmunity results from a 
breakdown in tolerance mechanisms that regulate autoreactive lymphocytes (10, 13).  Central 
tolerance mechanisms, such as deletion and receptor editing, regulate immature B cells 
specific for high avidity, membrane-bound self-antigens (20, 24, 27, 35, 36).  Peripheral 
tolerance mechanisms regulate bone marrow emigrants through deletion (37), positive 
selection into the B1 compartment (26, 32), functional ignorance of low affinity antigens (43, 
44), and anergy (22, 28, 30, 33, 40).  Early studies indicated that dysregulated T-dependent 
immune responses are responsible for the break in tolerance because the pathogenic 
autoantibodies are somatically mutated, class switched IgGs.  However, recent studies have 
revealed that T-independent immune responses may also lead to somatically mutated, class 
switched IgGs (205).  Several studies implicate innate immune responses in the initiation of 
tolerance.  First, bacterial or viral infection is correlated with the onset of disease (206).  
Second, inappropriate removal of apoptotic debris through complement and FcR and genetic 
defects in these receptors are associated with SLE.  Last, activation of autoreactive B cells 
via Toll-like Receptors (TLRs) facilitates disease as TLR7-deficient mice are protected from 
disease (86).  Hence, innate immune responses can play inflammatory or regulatory roles in 
lupus. 
Recent studies have investigated the regulation of B cells during innate immune 
responses.  TLR9 is required for activation of rheumatoid factor B cells through anti-
chromatin immune complexes (83), and dual ligation of TLR9 and B cell receptor (BCR) 
activates anti-chromatin B cells (84).  The mechanisms that regulate B cells specific for 
61
nuclear self-antigens during TLR-mediated activation remain unclear.  In the neo-self-
antigen system where all B cells recognize hen egg lysoszyme (HEL), TLR9 and TLR4-
induced Ig secretion was regulated by ERK.  In this study, continuous binding of the BCR to 
self-antigen elevated ERK activity which inhibited TLR4- and TLR9-induced plasma cell 
differentiation (45, 207).  Thus, chronic BCR stimulation regulates some anergic B cells 
during innate immune responses. 
Recently, we described a novel mechanism of tolerance regulating autoreactive B 
cells during innate immune responses.  Chronically antigen-experienced B cells are regulated 
by LPS-activated myeloid dendritic cells (myDCs) and macrophages (Ms), and repression 
of Ig secretion is readily reversed upon removal of these populations (160).  The repressive 
effect is mediated by the secretion of soluble factors, as LPS-activated DC and M
conditioned medium (CM) repressed Smith (Sm)-specific Ig secretion.  Further investigation 
into the identity of the soluble repressive factors revealed that DCs secrete IL-6 (160) and 
Ms secrete IL-6 and soluble CD40L (sCD40L) (Kilmon et al, manuscript submitted) that 
repress Ig secretion.  These results were surprising considering the role of IL-6 in promoting 
plasma cell differentiation and CD40L in activating acutely-stimulated B cells.  However, 
only chronically antigen-experienced, but not acutely-stimulated B cells, are repressed by IL-
6 and sCD40L (160) (Kilmon et al, manuscript submitted).  The data indicate that 
autoreactive B cells are regulated beyond chronic antigen-induced BCR desensitization, and 
suggest that the response of B cells to IL-6 and sCD40L is reprogrammed depending on the 
state of chronic BCR stimulation.  Significantly, lupus-prone mice are defective in DC and 
M-mediated repression, coincident with defects in IL-6 and CD40L secretion (208) 
(Kilmon et al, manuscript submitted).  Thus, these findings suggested that overcoming 
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tolerance in SLE may be associated with defects in the repression of autoreactive B cells by 
myDCs and/or Ms. 
In this report, we show that IL-6-deficient DCs and IL-6 x CD40L-deficient Ms
partially repress Ig secretion, suggesting the presence of a third repressive factor. 
Neutralization of TNF in CM from LPS-activated IL-6-/- DC and LPS activated IL-6-/- x 
CD40L-/- M relieved repression of Sm-specific Ig secretion.  Like previous findings with 
IL-6 and sCD40L, chronically antigen-experienced, but not naïve B cells are susceptible to 
repression by TNF. Significantly, MRL/lpr DCs and Ms are defective in secreting TNF.
Collectively, the data show that DCs and Ms secrete soluble factors, IL-6, sCD40L, and 
TNF, that prevent autoantibody production during innate immune responses, and that the 
lack of these factors contribute to autoimmunity. 
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Materials and Methods 
Mice 
C57BL/6J (B6) non-transgenic, C57BL/6-Tg(IghelMD4)4Ccg/J Ig (HEL-Ig) transgenic, 
C57BL/6-Tg(ML5sHEL)5Ccg/J (soluble HEL) transgenic (21), B6.129S2-Il6tm1Kopf/J        
(IL-6-/-), B6.129S2-Tnfsf5tm1Imx/J (CD40L-/-), B6;129S6-Tnftm1Gkl/J (TNF-/-), and MRL/MpJ-
Faslpr/J (MRL/lpr) mice were purchased from The Jackson Laboratory.  2-12H/V8/C-/- Ig 
transgenic mice were previously described (33, 160).  MRL/lpr mice were used at 6-10 
weeks old.  All other mice were used at 9-16 weeks old.  All studies were approved by the 
Institutional Animal Care and Use Committee. 
 
Reagents and Antibodies 
Recombinant IL-6 (rIL-6) and antibodies to IL-6, CD40L, and hamster IgG3 (isotype control 
for anti-CD40L) were purchased from BD Biosciences, TEPC 183 and Escherichia coli 
055:B5 LPS from Sigma-Aldrich, mouse GM-CSF, IL-4, and M-CSF from PeproTech, and 
CFSE from Invitrogen.  54.1 (3-83 idiotype, isotype control for anti-IL-6), 187.1 (anti-), 
HB100 (anti-IgMa), and B7.6 (anti-IgM) were purified from hybridoma culture supernatant.  
Recombinant TNF (rTNF) and recombinant sCD40L (rsCD40L) were purchased from 
R&D Systems.  Rabbit polyclonal anti-TNF was obtained from Vic Johnson 
(CDC/NIOSH/HELD, West Virginia) and purified by Protein A affinity.  The rabbit 
polyclonal anti-Syk was prepared against residues 257-352 of the murine Syk linker region 
and provided by John Cambier (University of Colorado Health Science Center, CO).   
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Bone marrow-derived DC (BMDC) and M (BMM) Cultures 
BMDCs (95% pure) and BMMs (98% pure) were generated as previously described (160).  
Conditioned medium (CM) was made from 1x104 BMDCs and BMMs (0.2 ml) cultured 4 
days with or without LPS (30 µg/ml). 
 
TNF expressing CHO cell line 
RNA was prepared from B6 DCs treated with LPS (30 µg/ml) for 6 hours by solubilization in 
Trizol (Invitrogen).  cDNA was generated by reverse transcription using random hexamer 
primers and M-MLV reverse transcriptase (Invitrogen).  The TNF cDNA was amplified by 
PCR using TNF-specific primers (GenBank Accession #NM_013693; 5’ – 
CCTCAGCGAGGACAGCAAGG – 3’ and 5’ – CCTTCACAGAGCAATGACTCC – 3’), 
subcloned into pCR2.1 TA TOPO vector (Invitrogen), and then cloned into the EcoR1 site of 
pHSPG-EGFP mammalian expression vector (Lishan Su, University of North Carolina).  
pHSPG containing the TNF DNA sequence (5 µg) was transiently transfected in Chinese 
Hamster Ovary (CHO) cells (5x106) (American Type Culture Collection) by nucleofection 
according to manufacturer’s instructions (Amaxa, Cell Line Nucleofector Kit T, Program U-
023).  CHO-TNF supernatant was harvested on day 2, and the levels of TNF quantitated 
to be 15 ng/ml (ELISA). 
 
B cell Purification and Culture 
B cells were isolated from spleens by negative selection (Easy Sep, StemCell Technologies) 
(160).  B cells were 85-93% pure as determined by flow cytometry.  1x105 purified B cells 
were cultured with LPS (30 µg/ml) for 4 days.  rIL-6, rsCD40L, rTNF, CHO-TNF,
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BMDC or BMM conditioned media (CM) (25% of final volume) were added to B cell 
cultures on day 0.  The IL-6 in CM was neutralized with either anti-IL-6 antibody or a 
control rat IgG1 antibody (54.1).  Soluble CD40L in CM was neutralized with either anti-
CD40L or control hamster IgG3 antibody.  TNF in CM was neutralized with either anti-
TNF or control anti-Syk. 
 
ELISAs 
IgMa/ (encoded by 2-12H/V8/C-/-) was captured with anti- (187.1) and detected with 
biotinylated anti-IgMa (HB100) and Streptavidin-AP as previously described (33).  IgM 
(encoded by B6) was captured with anti-IgM (clone 33-60) and detected with biotinylated 
anti-IgM (B7.6) and Streptavidin-AP.  Purified mouse IgMa/ (TEPC 183) served as the 
standard control.  Anti-HEL IgMa was captured with soluble HEL and detected with 
biotinulated anti-IgMa (HB100) and Streptavidin-AP as previously described (22).  Anti-HEL 
IgMa (clone E1) was used as the standard control.  IgMa/, IgM, and anti-HEL IgMa levels 
were plotted as “percent of control” defined by the level of Ig secretion in LPS-stimulated B 
cell cultures (100%).  TNF was quantitated by capturing with anti-TNF (clone TN3-19, 
eBioscience) and detecting with biotinylated polyclonal anti-TNF (eBioscience) and 
Streptavidin-AP.  rTNF served as the standard control. 
 
CFSE-based Proliferation Assay 
Purified B cells were resuspended at 1x106 cells/ml in pre-warmed 0.1% BSA/PBS and 
labeled with CFSE at a final concentration of 0.4 µM for 10 minutes at 37oC.  The cells were 
then washed with IMBM containing 5% FCS.  CFSE-labeled cells were stimulated with LPS 
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(30 µg/ml) in the presence or absence of rTNF (50 ng/ml) as described above.  After 3 
days, the cells were harvested and CFSE fluorescence intensity was analyzed by flow 
cytometry. 
 
Statistical Analysis 
Statistical analysis was done using the Student’s t test.  p values < 0.05 were considered 
significant and denoted by *.  
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Results 
TNF Secreted by DCs and Ms represses Ig secretion.
Maintaining B cell tolerance during activation of the innate immune system is crucial in 
preventing autoimmunity.  We previously showed that IL-6 and soluble CD40 ligand 
(sCD40L) secreted by TLR4-stimulated myeloid DCs (myDCs) and Ms represses Ig 
secretion by chronically antigen-experienced B cells (160) (Kilmon et al, manuscript 
submitted).  Although neutralizing antibodies to IL-6 restored IgMa/ levels to 75% of 
control in B6 DC conditioned medium (CM) (160), we were surprised to find that IL-6-/- DC 
CM repressed 45% of secretion (Figure 3.1A).  This suggests that DCs secrete another 
repressive factor.  To identify the third repressive factor, we neutralized IL-6-/- DC CM with 
a panel of antibodies.  As shown in Figure 3.1A, anti-TNF restored 83% of Ig secretion, a 
level that was not statistically different from control cells (B cells + LPS; p value = 0.898); 
while an unrelated antibody failed to relieve repression.  Consistent with the idea that TNF
contributes to the regulation of Ig secretion, CM derived from LPS activated TNF-/- DC 
repressed 33% of Ig secretion compared to 44% of Ig secretion by B6 DC CM (Figure 3.1B; 
p value = 0.010).  Further, neutralization of CM from TNF-/- DCs with anti-IL-6 restored 
127% of Ig secretion.  These data suggest that DCs secrete TNF as a second repressive 
factor that regulates autoreactive B cells    
To corroborate the idea that TNF regulates Ig secretion by autoreactive B cells we 
assessed if recombinant TNF was repressive. Similar to the neutralization data, 50 ng/ml of 
rTNF repressed 29% of Ig secretion (Figure 3.1C; p value = 0.00003).  Although rTNF
repressed Ig secretion, it was significantly less potent compared to rIL-6, which repressed 
75%, and rsCD40L, which represses 74% of Ig secretion (160) (Kilmon et al, manuscript 
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submitted).  Further, the amount of recombinant protein required was beyond physiologic 
levels.  This might be explained by low bioactivity in the commercial product because 
homotrimers of TNF are required for biological activity.  To address this possibility, we 
transiently expressed murine TNF in Chinese Hamster Ovary (CHO) cells where TNF is 
constitutively expressed in the culture supernatants at levels of 15 ng/ml.   Coculture of Sm-
specific B cells with 3.4 ng/ml of CHO-expressed TNF repressed 39% of Ig secretion (data 
not shown), compared to 29% when the commercial recombinant product was used at 50 
ng/ml (Figure 3.1C).  Further titration of the bioactive TNF did not repress additional 
IgMa/ levels indicating that approximately 30% repression is maximal.  
To assess if the ability of TNF to regulate Ig secretion was enhanced by IL-6, we 
cultured Sm-specific B cells with optimal levels of TNF and suboptimal levels of IL-6 then 
assessed IgMa/ secretion.  IL-6 at 5 ng/ml was chosen because this level represses 32% of 
secretion, approximately the same amount as optimal TNF levels (50 ng/ml; 29% of 
secretion) (Figure 3.1C).  Interestingly, the ability of rTNF to repress was enhanced in the 
presence of suboptimal levels of rIL-6, although statistical significance was not reached in 
three experiments (Figure 3.1C; p value = 0.057).  We are continuing to test this using the 
TNF from CHO sup to see if this effect is significant.  Collectively, the data indicate that 
DCs secrete IL-6 and TNF to the regulate Ig secretion by Sm-specific B cells, but TNF is 
a less potent repressor compared to IL-6.  The ability of TNF to repress may be enhanced 
by IL-6, although additional experiments are required.  
To determine if IL-6 and TNF were the only repressive factors secreted by DCs, we 
undertook two approaches.  In the first, we used neutralizing antibodies to IL-6, TNF, or
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IL-6 + TNF to abrogate the repressive ability of B6 CM.  CM where IL-6 was neutralized 
repressed 18% of Ig secretion, while CM with TNF neutralized repressed 26% of secretion.  
In contrast, neutralization of both IL-6 and TNFW restored Ig secretion to control levels (p
value = 0.695, Figure 3.2A).  This supports the idea that IL-6 and TNF are the only 
repressive factors made by DCs.  In a second approach, we generated IL-6-/- x TNF-/- mice.   
We predicted that if IL-6 and TNF were the only repressive factors, LPS-stimulated DCs 
from IL-6-/- x TNF-/- mice would fail to repress Ig secretion.  As shown in Figure 3.2B, CM 
prepared from LPS-stimulated IL-6-deficient DCs repressed 45% of Ig secretion.  Similarly 
CM from TNF-deficient DCs repressed 42%.  In contrast, DC CM from IL-6-/- x TNF-/- 
repressed 17% of Ig secretion, a value that was not statistically different than control cells (p
value =  0.106 ).  The data confirm that IL-6 and TNF are the only soluble mediators 
secreted by TLR4-stimulated DCs to regulate autoreactive, Sm-specific B cells during innate 
immune responses. 
Ms regulate autoreactive B cells by secreting IL-6 and sCD40L.  Similar to the 
findings with DCs, neutralizing B6 M CM with IL-6 and sCD40L restored IgMa/ levels to 
95% of control (Kilmon et al, manuscript submitted); however, IL-6-/- x CD40L-/- M CM 
repressed 48% of Ig secretion (Figure 3.3A).  To assess the possibility that M-derived 
TNF regulates autoreactive B cells, we co-cultured LPS-activated IL-6-/- x CD40L-/- M
CM with Sm-specific B cells.  As shown in Figure 3.3A, neutralization of TNF in the IL-6-/- 
x CD40L-/- M CM restored Ig secretion to 81% of control (p value = 0.060); a level that 
again was not statistically different from control cells (LPS-stimulated B cells).  To further 
assess if other factors secreted by Ms contributed to the regulation of autoreactive B cells 
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we neutralized sCD40L in IL-6-/- x TNF-/- M CM (Figure 3.3B).  Ig secretion was 
partially restored (from 69% to 81% secretion), indicating that TLR4-activated Ms and 
DCs regulate autoantibody secretion in part through the production of TNF. It is of interest 
to note that the dichotomy between the ability of IL-6-/- DCs and IL-6-/- x CD40L-/- Ms to 
repress Ig secretion compared to the ability of TNF-neutralized CM to repress Ig secretion 
might suggest that Ms compensate for the lack of IL-6 and CD40L by enhancing secretion 
of TNF. However, the amounts of TNF in IL-6-/- DC CM and IL-6-/- x CD40L-/- M CM 
compared to B6 CM were not different (data not shown). 
To definitively establish if IL-6, sCD40L and TNF are the only repressive factors 
secreted by Ms to repress Ig secretion by autoreactive B cells, we generated IL-6-/- x 
CD40L-/- x TNF-/- mice.  Although we have the mice, it remains to be determined whether 
M CM from these mice will repress LPS-induced Ig secretion.  We predict that because 
neutralizing TNF relieved the repressive effect of IL-6-/- x CD40L-/- M CM, that M CM 
from IL-6-/- x CD40L-/- x TNF-/- mice will not repress Ig secretion.  Collectively, the data 
suggest that during innate immune responses DCs and Ms secrete IL-6, sCD40L, and 
TNF that repress the secretion of Sm-specific autoantibody.  
 
TNF represses Sm-specific B cells but not high affinity lysozyme-specific cells. 
We previously demonstrated that IL-6 (160) and sCD40L (Kilmon et al, manuscript 
submitted) repress TLR4-stimulated chronically antigen-experienced B cells, but do not 
affect acutely-stimulated naïve B cells.  The data suggest that chronically-stimulated 
autoreactive B cells reprogram their responses to IL-6 and sCD40L to prevent the secretion 
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of autoantibody during innate immune responses.  TNF is known to enhance naïve B cell 
activation and proliferation (209-213).  Therefore, we hypothesized that TNF, like IL-6 and 
sCD40L, would selectively repress chronically antigen-experienced B cells.  rTNF had no 
effect on Ig secretion by LPS-stimulated naïve B cells from nonautoimmune B6 mice.  
Likewise, LPS-induced Ig secretion by naïve HEL-specific B cells (HEL-Ig) was similar in 
the presence or absence of rTNF (Figure 3.4A).  Thus, TNF does not affect LPS-
stimulated Ig secretion by naïve B cells as predicted.  Significantly, rTNF did not repress Ig 
secretion by HEL-specific B cells chronically exposed to soluble HEL (HEL-Ig x sHEL) 
(Figure 3.4B).  The data show that TNF does not repress all chronically-stimulated B cells, 
and suggest that some autoreactive B cells are susceptible to repression by TNF, whereas 
others are not.  The BCR on Ig transgenic B cells from 2-12H/V8 mice has a low to 
moderate affinity for Sm, and these B cells are susceptible to repression by TNF. The BCR 
on Ig transgenic B cells from HEL-Ig x sHEL mice has a high affinity for sHEL.  These B 
cells are repressed by IL-6 and CD40L, but not by TNF. We determined that TNF is less 
potent as a repressive factor than IL-6 and sCD40L (Figure 3.1C).  Consequently, TNF may 
not be strong enough to repress B cells with high affinity BCR specific for self-antigen.  To 
confirm this hypothesis, we will test the ability of TNF to repress autoreactive B cells from 
other low affinity Ig transgenic models. 
 
TNF does not affect proliferation of B cells as a means of repressing Ig secretion.
Plasma cell differentiation requires B cell proliferation and upregulation of transcriptional 
regulators, Blimp-1 and XBP-1.  LPS-stimulated autoreactive B cells are allowed to 
proliferate in the presence of IL-6 and sCD40L; however, the production of Blimp-1 and 
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XBP-1 mRNA is blocked preventing the formation of antibody secreting cells (Rutan et al, 
manuscript in preparation; Kilmon et al, manuscript submitted).  To determine whether 
TNF affects critical regulatory steps in plasma cell differentiation, we examined its effect 
on proliferation.  To assess proliferation, we labeled B cells with CFSE, stimulated cells with 
LPS in the presence or absence of rTNF, and analyzed proliferation by flow cytometry 
(Figure 3.5).  TNF did not affect proliferation of B cells from 2-12H/V8 or HEL-Ig x 
sHEL mice, nor did it affect naïve B cells from B6 or HEL-Ig mice.  The data show that 
LPS-stimulated B cells in the presence or absence of rTNF had overlapping CFSE 
histogram plots, indicating that similar number of cells existed in each generation in the 
presence or absence of rTNF. Thus, TNF repression of Sm-specific B cells was not due to 
decreased proliferation.  TNF might block Blimp-1 or XBP-1 transcription, thereby 
inhibiting plasma cell differentiation and Sm-specific Ig secretion.  Future experiments will 
determine the effect of rTNF on Blimp-1 or XBP-1 transcription by real time RT-PCR. 
 
DCs and Ms from MRL/lpr mice are defective in secreting TNF in response to TLR 
stimulation.
DCs and Ms secrete IL-6, sCD40L, and TNF that repress Ig secretion by chronically 
antigen-experienced B cells and suggest that overcoming tolerance in SLE may be associated 
with defects in the repression of autoreactive B cells by myDCs and/or Ms.  We previously 
showed that DCs and Ms from lupus-prone mice are defective in repressing Ig secretion, 
coincident with defects in TLR4-stimulated secretion of IL-6 and sCD40L (208) (Kilmon et 
al, manuscript submitted).  To determine if lupus DCs and Ms were also defective in 
secreting TNF, we measured TNF secretion in culture by ELISA.  LPS-stimulated 
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BMDCs from lupus-prone MRL/lpr secreted significantly less TNF than B6 (p value = 
0.00002, Figure 3.6A).  BMMs from 7 of 9 MRL/lpr mice secreted less TNF compared to 
B6 (Figure 3.6B).  Thus, MRL/lpr mice also exhibit defects in secretion of TNF.
Collectively, the data show that defects in DC and M-mediated regulation of autoantibody 
secretion exhibited by MRL/lpr mice are coincident with defects in all three repressive 
soluble factors. 
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Discussion 
Previous studies into the mechanisms of B cell tolerance have focused on 
antigen/BCR mediated regulation of autoreactive or chronically antigen-experienced B cells.  
However, the regulation of chronically antigen-experienced B cells during polyclonal 
activation is less understood.  Recently, we described that chronically antigen-experienced B 
cells are regulated by LPS-activated DCs and Ms (160).  In this report, we show that DCs 
and Ms secrete TNF, in addition to IL-6 and sCD40L, that selectively repress Ig secretion 
by chronically antigen-experienced B cells during innate immune responses.  Thus, we have 
identified a novel mechanism of tolerance mediated by DCs and Ms, and demonstrated 
novel roles for IL-6, sCD40L, and TNF in Ig repression. 
Neutralization studies suggest that all of the repressive soluble factors have been 
identified.  IL-6-/- DC CM and IL-6-/- x CD40L-/- M CM were just as capable of repressing 
chronically antigen-experienced B cells as DC CM and M CM from B6 mice.  Neutralizing 
TNF in IL-6-/- DC CM (Figure 3.1) and IL-6-/- x CD40L-/- M CM (Figure 3.3) relieved the 
repressive effect (DCs do not express CD40L).  Hence, the data suggest that TNF is 
responsible for Ig repression in the absence of IL-6 and sCD40L.  However, when LPS-
stimulated Sm-specific B cells were cultured with recombinant TNF, Ig secretion was only 
repressed by 29% (Figure 3.2) in comparison IL-6-/- DC CM and IL-6-/- x CD40L-/- M CM 
which repressed 45% and 48% of Ig secretion respectively (Figure 3.1 and 3.3).  Thus, a 
cofactor secreted by DCs and Ms may exist that allows TNF to exert its full repressive 
potential on chronically antigen-experienced B cells.  This cofactor is not capable of 
repression alone, as IL-6-/- x TNF-/- DC CM did not repress Ig secretion (Figure 3.2).  We 
expect that future experiments will also show that IL-6-/- x CD40L-/- x TNF-/- M CM do 
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not repress Ig secretion.  It would be interesting to determine whether the possible cofactor is 
secreted by IL-6-/- x TNF-/- DCs and present in CM.  If so, we would predict that the 
cofactor in IL-6-/- x TNF-/- DC CM could restore the full repressive potential of rTNF, and 
that autoreactive B cells cultured in the presence of IL-6-/- x TNF-/- DC CM and rTNF
would repress Ig secretion similar to B6 DC CM. 
The repressive functions of IL-6, sCD40L, and TNF during innate immune 
responses challenge what we currently understand about their roles in promoting B cell 
responses.  B cells that have been acutely stimulated and exposed to IFN-/ induce Ig 
secretion in response to IL-6 (140).  In addition, IL-6 indirectly promotes B cell responses by 
blocking the repressive effect of regulatory T cells, thus activating CD4+ T cells (129).  
Antigen-stimulated B cells require T cell help to produce Ig in the form of CD40L, and lack 
of CD40L or blocking CD40 stimulation on B cells impairs Ig production (38).  TNF
enhances cytokine or mitogen-stimulated B cell proliferation and Ig secretion (209-213), and 
membrane TNF expressed on viral-infected CD4+ T cells mediates polyclonal B cell 
activation (214, 215).  Thus, previous studies demonstrate IL-6, CD40L, and TNF act as 
positive regulators of acutely-stimulated B cell responses.  Importantly, these studies used B 
cells from non-transgenic models where the proportion of autoreactive B cells is either very 
low or nonexistent.  Our data show that IL-6 (160), CD40L (Kilmon et al, manuscript 
submitted), and TNF act as negative regulators of chronically antigen-stimulated B cells.  
Thus, the history of BCR ligation determines whether B cells are susceptible to IL-6, CD40L, 
and TNF-mediated repression, and suggest that chronic stimulation of the BCR reprograms 
responses to these soluble factors. 
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Not only is the history of BCR ligation critical in determining whether B cells are 
susceptible to IL-6, CD40L, and TNF-mediated repression, but the data suggest that BCR 
affinity may be important in this fate decision.  TNF repressed Ig secretion by low to 
moderate affinity, Sm-specific B cells, but did not affect Ig secretion by high affinity (>109
M), HEL-specific B cells chronically exposed to soluble HEL (HEL-Ig x sHEL) (Figure 
3.3B).  TNF is less potent as a repressive factor than IL-6 and sCD40L.  Consequently, 
TNF may not be strong enough to repress B cells with high affinity BCR specific for self-
antigen.  To confirm this hypothesis, we plan to test the ability of TNF to repress 
autoreactive B cells from other low affinity Ig transgenic models.  One potential model is the 
anti-insulin 125 Ig transgenic model.  Similar to anti-Sm 2-12H/V8 Ig transgenic B cells, 
125 Ig transgenic B cells express a BCR with low affinity for self-antigen (107 M) (216).  
These B cells do not undergo developmental arrest, but are anergic in the periphery and have 
characteristics of a B1-like subset (217, 218).  Significantly, SLE patients have higher 
frequencies of serum anti-insulin IgM antibodies than healthy controls (219).  Thus, the anti-
insulin Ig transgenic model having a low affinity BCR should prove useful in studying 
tolerance mediated by TNF.
The mechanisms of IL-6, sCD40L, and TNF repression are currently under 
investigation.  We have shown that IL-6 and sCD40L block transcription of Blimp-1 and 
XBP-1 important in plasma cell differentiation, thereby inhibiting or reducing LPS-
stimulated Ig secretion (160) (Kilmon et al, manuscript submitted).  Other studies have 
demonstrated that IL-6-mediated repression is ERK-dependent (Rutan et al, manuscript in 
preparation).  Interestingly, some chronically-stimulated autoreactive B cells exhibit chronic 
ERK activation making them refractory to TLR9-induced Ig secretion (45).  It is unknown, 
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however, whether chronic or acute ERK activation reprograms IL-6, CD40L, and TNF
responses in chronically-stimulated B cells. 
To validate that DC/M-mediated tolerance is important in disease, it is necessary to 
determine whether defective DC/M-mediated tolerance can cause disease in 
nonautoimmune mice or whether functional DCs and Ms can cure disease in autoimmune 
mice.  Bone marrow transplantion involving fractionated total body irradiation has been used 
to prevent and treat lupus in MRL/lpr mice (220).  This experiment can be modified to study 
the role of the repressive soluble factors in preventing disease.  If hematopoietic stem cells 
from IL-6-/- x CD40L-/- x TNF-/- are transplanted into irradiated MRL/lpr mice, we would 
predict from in vitro data that the mice will not be protected from disease because they lack 
the repressive soluble factors that regulate autoreactive B cells.  Because wildtype stem cell 
transplantion protects from lupus, this data would suggest that the lack of IL-6, CD40L, and 
TNF causes disease. 
Our data show that lupus-prone mice are defective in DC and M-mediated 
tolerance, coincident with defects in IL-6 (208), sCD40L (Kilmon et al, manuscript 
submitted), and TNF, suggesting that the lack of repressive soluble factors would cause 
disease in nonautoimmune mice.  However, it is difficult to predict the effect of IL-6, 
CD40L, and TNF deficiencies on autoimmunity in triple knock-out mice for several 
complicating reasons.  First, TNF is important for proper formation of the splenic 
architecture (221, 222).  TNF is required for the formation of primary B cell follicles, 
follicular DC networks, and germinal centers.  Secondly, CD40L is important in generating 
class-switched IgG pathogenic autoantibodies that cause disease.  As a result, the presence or 
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absence of autoimmune disease in IL-6-/- x CD40L-/- x TNF-/- mice would be difficult to 
interpret. 
The proper formation of splenic follicles and germinal centers is a significant variable 
in studying autoimmunity in IL-6-/- x CD40L-/- x TNF-/- mice.  To eliminate disrupted 
splenic architecture as a variable, we propose to transplant stem cells from IL-6-/- x CD40L-/- 
x TNF-/- mice into irradiated wildtype nonautoimmune mice.  This would generate IL-6, 
CD40L, and TNF deficient immune cells in the context of a properly structured spleen.  We 
could then adoptively transfer Ig transgenic autoreactive B cells into these mice and follow 
their break in tolerance by the presence of Ig transgenic autoantibody in the serum.  This 
experiment would prove that autoreactive B cells are regulated by IL-6, CD40L, and TNF
in vivo and that the lack of repressive soluble factors causes a break in tolerance. 
The experiments described above do not address the source of the repressive factors 
in vivo. Thus, they would not directly address the role of DCs and Ms in regulating 
autoimmunity.  The only way to determine the role of DC and M-derived IL-6, CD40L, 
and TNF is to create DC and M conditional knock-out mice for IL-6, CD40L, and TNF.
Using the cell specific conditional knock-out would allow for the proper formation of the 
splenic architecture and to restrict the deficiency of the repressive factors to DCs and Ms.  
Although this mouse would be a useful tool, it would not be a trivial task to create. 
The ultimate goal of understanding B cell tolerance mechanisms is to create more 
specific clinical therapies for the prevention and treatment of disease.  Interestingly, the use 
of antibodies against IL-6, TNF, and CD40L has been studied for the treatment of lupus for 
good reason.  IL-6, TNF, and CD40L all promote B cell activation, differentiation, and Ig 
production as previously described.  In addition, IL-6 and TNF are proinflammatory 
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cytokines that cause tissue damage.  Significantly, lupus patients with active disease have 
increased serum concentrations of IL-6, TNF, and CD40L (189, 223).  Thus, it was logical 
to think that blocking their actions would decrease autoreactive B cell activation and 
symptoms of disease.  However, our data suggest that these therapies would promote the 
break in tolerance of newly generated autoreactive B cells because IL-6, TNF, and CD40L 
repress chronically antigen-experienced B cells.  In fact, anti-TNF therapy has been found 
to cause autoimmunity or lupus-like symptoms in patients with several types of autoimmune 
syndromes including rheumatoid arthritis, Chrohn’s disease, and progressive multiple 
sclerosis (224-230).  Yet, the findings that lupus patients with active disease have increased 
serum concentrations of IL-6, TNF, and CD40L seem contradictary to our data.  
Preliminary studies suggest that autoreactive B cells from lupus-prone mice are not repressed 
by IL-6, sCD40L, and TNF, similar to naïve B cells but unlike autoreactive B cells from 
nonautoimmune mice (N. J. Wagner and B. J. Vilen, unpublished observations).  Thus, once 
B cells break tolerance in lupus patients, they may no longer be able to respond appropriately 
to the increased serum concentrations of repressive factors.  It would be interesting to 
determine whether autoreactive B cells from lupus mice pre-disease are capable of being 
repressed by the soluble factors and if this corresponds with normal serum levels of IL-6, 
sCD40L, and TNF.
In conclusion, therapies aimed at neutralizing the inflammatory effects of IL-6, 
sCD40L, and/or TNF may have short-term benefits in treating lupus nephritis, however in 
some patients, they may promote loss of tolerance in newly emerging B cells during innate 
immune activation. 
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Figure 3.1.  TNF secreted by DCs represses Ig secretion. Purified B cells (1x105) from 
2-12H/V8 mice were stimulated with LPS (30 µg/ml) in the presence or absence of (A) 
LPS-activated B6 DC CM , IL-6-/- DC CM, or IL-6-/- DC CM neutralized with control Ab 
(324 µg) or anti-TNF (324 µg), (B) LPS-activated B6 DC CM, TNF-/- DC CM, or TNF-/- 
DC CM neutralized with isotype-matched control Ab (50 µg/ml) or anti-IL-6 (50 µg/ml), (C) 
the indicated amounts of rIL-6, rsCD40L, or rTNF. Secreted IgMa/ levels were 
quantitated by ELISA from day 4 culture supernatant.  LPS-stimulated purified B cells 
(100%) secreted 1-10 µg/ml IgMa/. Data represent triplicate samples in at least 3 
experiments.  *p<0.05. 
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Figure 3.2.  IL-6 and TNF are the only repressive factors secreted by DCs. Purified B 
cells (1x105) from 2-12H/V8 mice were stimulated with LPS (30 µg/ml) in the presence or 
absence of (A) LPS-activated B6 DC CM or B6 DC CM neutralized with control Abs, anti-
IL-6 (50 µg/ml), anti-TNF (324 µg), or both, (B) LPS-activated B6 DC CM, IL-6-/- DC 
CM, TNF-/- DC CM, or IL-6-/- x TNF-/- DC CM.  Secreted IgMa/ levels were quantitated 
by ELISA from day 4 culture supernatant.  LPS-stimulated purified B cells (100%) secreted 
1-10 µg/ml IgMa/. Data represent triplicate samples in each of at least 3 experiments.  
*p<0.05. 
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Figure 3.3.  TNF secreted by Ms represses Ig secretion. Purified B cells (1x105) from 
2-12H/V8 mice were stimulated with LPS (30 µg/ml) in the presence or absence of (A) 
LPS-activated B6 M CM, IL-6-/- x CD40L-/- M CM, or IL-6-/- x CD40L-/- M CM 
neutralized with control Ab (324 µg) or anti-TNF (324 µg), (B) LPS-activated B6 M CM, 
IL-6-/- x TNF-/- M CM, or IL-6-/- x TNF-/- M CM neutralized with control Ab (10 
µg/ml) or anti-CD40L (10 µg/ml).  Secreted IgMa/ levels were quantitated by ELISA from 
day 4 culture supernatant.  LPS-stimulated purified B cells (100%) secreted 1-10 µg/ml 
IgMa/. Data represent triplicate samples in each of at least 3 experiments.  *p<0.05. 
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Figure 3.4.  TNF represses only Sm-specific B cells. Purified B cells (1x105) from (A) 
B6, HEL-Ig, or (B) HEL-Ig x sHEL mice were stimulated with LPS (30 µg/ml) in the 
presence or absence rTNF for 4 days.  Total IgM (B6) and anti-HEL IgMa (HEL-Ig and 
HEL-Ig x sHEL) were quantitated by ELISA.  LPS-stimulated purified B cells (100%) 
secreted 44-65 µg/ml (B6), 11-17 µg/ml (HEL-Ig), and 3-5 µg/ml (HEL-Ig x sHEL). Data 
represent triplicate samples in each of at least 3 experiments.  *p<0.05. 
 
84
Figure 3.5.  TNF does not affect proliferation of B cells. Proliferation of LPS-stimulated 
(30 µg/ml), CFSE-labeled B cells from 2-12H/V8, HEL-Ig x sHEL, B6, and HEL-Ig mice, 
in the presence (black line) or absence (gray fill) of rTNF (50 ng/ml), was determined on 
day 3 by FACS analysis.  Data is representative of 3 experiments. 
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Figure 3.6. DCs and Ms from MRL/lpr mice are defective in TNF secretion. 1x104
(A) BMDCs or (B) BMMs were stimulated with LPS (30 µg/ml).  TNF was quantitated 
by ELISA from the day 4 culture supernatants.  Data represent at least 9 mice per group. (
B6, MRL/lpr) *p < 0.05.
 
CHAPTER IV 
Potential Mechanisms for the TLR Defect in Lupus-Prone Mice
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Abstract 
Toll-like Receptors (TLRs) polyclonally activate dendritic cells (DCs) and macrophages 
(Ms) during innate immune responses.  TLR stimulation induces secretion of pro-
inflammatory cytokines, including IL-6, soluble CD40L (sCD40L), and TNF. We recently 
described that these factors secreted by DCs and Ms selectively repress chronically 
antigen-experienced B cells during innate immune responses.  Significantly, DC and M-
mediated tolerance is defective in lupus-prone MRL/lpr mice, coincident with defects in 
TLR-induced IL-6, sCD40L, and TNF secretion.  Thus, the data suggest that defects in DC 
and M-mediated tolerance contribute to autoimmunity.  Investigation into the mechanism 
of the TLR defect showed that MRL/lpr DCs are unable to sustain signaling through the 
TLR, and suggest that lupus DCs quickly become tolerized to LPS.  Several negative 
regulators of TLR signaling could play a role in this phenomenon; however, only a few of 
them have been associated with autoimmune disease.  Potential mechanisms for the 
molecular defect involve STAT and SOCS proteins, apoptotic cells, and mechanisms of 
endotoxin tolerance.  The purpose of this chapter is to discuss early observations as we 
investigate the TLR defect in DCs.  Determining the cause of the TLR defect in lupus-prone 
mice could identify a genetic signature for individuals susceptible to lupus disease. 
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Introduction 
B cell tolerance mechanisms are critical in regulating autoreactive B cells generated 
during development in the bone marrow.  These tolerance mechanisms include deletion (37), 
positive selection into the B1 compartment (26, 32), receptor editing (35-37), functional 
ignorance of low affinity antigens (43, 44), and anergy (22, 28, 30, 33, 40).  The breakdown 
of these mechanisms leads to uncontrolled autoimmunity and diseases like Systemic Lupus 
Erythematosus (SLE). 
We recently described a novel of mechanism of tolerance involving dendritic cells 
(DCs) and macrophages (Ms) that regulate chronically stimulated autoreactive B cells in 
the periphery (160).  Polyclonal activators stimulate myeloid DCs (myDCs) and Ms
through TLRs to secrete soluble factors, IL-6, soluble CD40L (sCD40L), and TNF, that 
differentially regulate naïve and chronically antigen-experienced B cells.  IL-6, sCD40L, and 
TNF selectively repress LPS-stimulated autoreactive B cells while having no effect on 
naïve B cells (160) (Kilmon et al, manuscript submitted; Chapter 3).  We propose that 
chronic BCR ligation by self-antigen reprograms IL-6, sCD40L, and TNF receptor-
mediated outcomes allowing naïve B cells to produce Ig in response to polyclonal 
stimulation while simultaneously repressing autoreactive B cells from producing 
autoantibody. 
These findings suggested that overcoming tolerance in SLE may be associated with 
defects in the repression of autoreactive B cells by myDCs and/or Ms. Significantly, DC 
and M-mediated tolerance is defective in lupus-prone MRL/lpr mice (208) (Kilmon et al, 
manuscript submitted).  DCs and Ms from MRL/lpr mice are less efficient than 
nonautoimmune mice at repressing autoantibody secretion.  The defects in DC and M-
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mediated tolerance are coincident with defects in secreting the repressive soluble factors, IL-
6, sCD40L, and TNF. The data suggest that defects in DC and M-mediated tolerance 
play a role in autoimmunity.  Determining the cause of the TLR defect in lupus-prone mice 
could identify a genetic signature for individuals susceptible to lupus disease. 
Investigation into the mechanism of the TLR defect showed that MRL/lpr DCs are 
unable to sustain signaling through the TLR.  LPS stimulation of MRL/lpr DCs initially 
induces IB phosphorylation important for activation of the transcription factor NF-B.  
However, IB phosphorylation is not sustained, resulting in reduced NF-B DNA binding 
and IL-6 mRNA synthesis (208).  The ability to sustain signaling through the TLR is critical 
for normal secretion of IL-6 by DCs (180).  Hence, this defect in MRL/lpr DCs carries 
significant consequences for the production of IL-6 and other cytokines.  Thus, the data 
suggest that lupus DCs quickly become tolerized to LPS causing defective production of 
TLR-stimulated cytokines. 
 
There are several negative regulators of TLR signaling that could play a role in this 
phenomenon; however, only a few of them have been associated with autoimmune disease.  
Potential mechanisms for the molecular defect involve STAT and SOCS proteins, apoptotic 
cells, and mechanisms of endotoxin tolerance.  The purpose of this chapter is to discuss early 
observations as we investigate the TLR defect in DCs. 
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Materials & Methods 
Mice 
MRL/MpJ-Faslpr/J (MRL/lpr) and C57BL/6J (B6) mice were purchased from The Jackson 
Laboratory.  All mice were used at 6-10 weeks old.  All studies were approved by the 
Institutional Animal Care and Use Committee. 
 
Reagents and Antibodies 
Recombinant IL-6 was purchased from BD Biosciences, E. coli 0111:B4 LPS from List 
Biological Laboratories, mouse GM-CSF and IL-4 from PeproTech.  Antibodies to phospho-
IB, phospho-STAT3 Y705, and STAT3 protein were purchased from Cell Signaling, 
IB and -tubulin from Santa Cruz, and IgG HRP from Promega. 
 
Bone marrow-derived DC (BMDC) Cultures 
Bone marrow single cell suspensions were prepared from the femurs and tibias of B6 and 
MRL/lpr mice.  Following red blood cell lysis, cells were cultured in GM-CSF (10 ng/ml) 
and IL-4 (10 ng/ml) for 5 days.  BMDCs were >95% CD11c+.
Immunoblotting 
BMDCs (2x106) were stimulated with recombinant IL-6 (10 ng/ml) and/or re-purified List 
LPS (15 µg/ml) and solublized in lysis buffer containing 1% NP-40, 150 mM NaCl, 10 mM 
Tris (pH 7.5), 2 mM sodium o-vanadate, 1 mM PMSF, 0.4 mM EDTA, 10 mM NaF, and 1 
µg/ml each of aprotinin, leupeptin, and 1-anti-trypsin.  Detergent insoluble material was 
removed by centrifugation at 12,000 x g for 10 minutes.  Proteins were resolved by SDS-
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PAGE and transferred onto PVDF membrane.  Phospho-IB, IB, phospho-STAT3 
Y705, STAT3, and  tubulin were immunoblotted with HRP tagged antibodies and detected 
by enhanced chemiluminescence (ECL, Amersham Biosciences).   
 
Real time RT-PCR  
RNA was prepared from BMDCs treated with re-purified LPS (15 µg/ml) by solubilization in 
Trizol (Invitrogen).  Reverse transcription was performed with random hexamer primers and 
M-MLV reverse transcriptase (Invitrogen).  RT-PCR was performed on cDNA using ABgene 
QPCR SYBR Green Master Mix and the ABI 7000 sequence detection system with primers 
for SOCS1, SOCS3, and the 18s housekeeping gene (Table 4.1) as a control.  SOCS1 and 
SOCS3 mRNA transcript levels were normalized to the amount of 18s ribosomal RNA 
transcription using the 2CT method according to the following equation: relative RNA 
expression = 2^ [-(gene of interest – 18s units)], and plotted as fold over background in 
unstimulated DCs. 
 
Table 4.1.  Real time RT-PCR primers 
 
SOCS1 forward 5’ – CACCTTCTTGGTGCGCG – 3’ 
SOCS1 reverse 5’ – AAGCCATCTTCACGCTGAGC – 3’ 
SOCS3 forward 5’ – TGAGCGTCAAGACCCAGTCG – 3’ 
SOCS3 reverse 5’ – CACAGTCGAAGCGGGGAACT – 3’ 
18s rRNA forward 5’ – TCAAGAACGAAAGTCGGAGGTT – 3’ 
18s rRNA reverse 5’ – GGACATCTAAGGGCATCACAG – 3’ 
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Results and Discussion 
LPS-activated DCs and Ms secrete IL-6, sCD40L, and TNF that repress 
autoantibody production.  Secretion of these repressive factors is an important component of 
DC and M-mediated B cell tolerance during innate immune responses.  Hence, defects in 
secretion of IL-6, sCD40L, and TNF could contribute to autoimmunity.  We have 
previously shown that DCs and Ms from lupus-prone MRL/lpr mice are less efficient at 
repressing autoantibody secretion than nonautoimmune mice (208) (Kilmon et al, manuscript 
submitted).  In addition, DCs and Ms from several strains of lupus-prone mice are defective 
in secreting IL-6, sCD40L, and TNF in response to TLR stimulation.  In fact, a previous 
study showed that Ms from several autoimmune strains are defective in expressing pro-
inflammatory cytokines (158).  However, the authors were unaware of the importance of 
Ms in B cell tolerance and how defects in secretion of cytokines like IL-6 and TNF are 
associated with autoimmunity. 
Further investigation into IL-6 production by MRL/lpr DCs revealed differences in 
the ability to respond to different TLR ligands.  Interestingly, IL-6 secretion is defective 
when stimulated through TLR4 (LPS), TLR7 (R848), and TLR9 (CpG ODN), however, 
secretion is increased when stimulated through TLR3 (poly I:C) (208).  This indicates that 
not all TLRs are affected by this defect.  To corroborate these findings, we examined the 
induction of IB phosphorylation in response to TLR4 and TLR3 stimulation.  LPS induces 
early IB phosphorylation in MRL/lpr DCs but are unable to sustain phosphorylation like 
B6 DCs.  In constrast, poly (I:C)-induced IB phosphorylation was comparable between 
DCs derived from B6 and MRL/lpr mice (208).  Thus, signaling through TLR3 is not 
defective.  TLR4, TLR7, and TLR9 are similar in that they use signaling pathways dependent 
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on the MyD88 adaptor molecule, whereas TLR3 signals through a MyD88-independent 
pathway.  Hence, the data suggest that the defect in TLR signaling is in the MyD88-
dependent pathway. 
The finding that IB phosphorylation is not sustained, resulting in reduced NF-B
and AP-1 DNA binding and IL-6 mRNA synthesis (208), is significant for the production of 
IL-6.  The ability to sustain signaling through the TLR is critical for normal secretion of IL-6 
by DCs.  Yang et al showed that persistant TLR4 signals are required for normal DC 
secretion of IL-6 (180).  Therefore, the inability to sustain TLR signaling results in 
diminished IL-6 secretion.  Thus, it seems that lupus DCs quickly become tolerized to LPS 
causing defective production of TLR-stimulated cytokines. 
Endotoxin tolerance is a normal regulatory mechanism controlling cellular responses 
to bacterial products.  Upon ligand binding, MyD88 associates with the TLR and recruits 
IRAK4 and IRAK1.  Activation of IRAK1 leads to downstream phosphorylation of IB,
NF-B activation, and transcription of cytokines.  Endotoxin tolerance is associated with a 
reduction in IRAK1 expression, IRAK association with MyD88, and IB phosphorylation 
(231, 232).  We previously demonstrated that MRL/lpr DCs exhibit decreased sustained 
amounts of IB phosphorylation (208).  Here, we show that MRL/lpr DCs also exhibit 
reduced IRAK1 expression.  IRAK1 is normally degraded after transducing a signal.  
BMDCs from B6 mice express IRAK1 protein, and once stimulated by LPS, the majority of 
IRAK1 protein is degraded by 30 minutes (Figure 4.1).  In constrast, MRL/lpr BMDCs 
express reduced basal levels of IRAK1 with very little degradation (Figure 4.1), indicating 
minimal signal transduction through the TLR.  Thus, reduced expression of IRAK1 mimicks 
what has been observed in endotoxin tolerance.  The data suggest that MRL/lpr DCs have 
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become tolerant to LPS signaling.  We predict that IRAK association with MyD88 would 
also be diminished, correlating with reduced IB phosphorylation, NF-B activation, and 
IL-6 mRNA levels. 
MRL/lpr DCs are capable of transducing an early signal through the TLR, but are 
defective in sustaining signal transducation as previously described (208).  One possible 
mechanism for the defect is that the activity of a negative regulator of TLR signaling is 
enhanced in MRL/lpr DCs.  TLR-stimulated secreted products, including IL-6, could also 
feedback onto the cell in an autocrine manner to regulate TLR signaling.  To determine if IL-
6 affects TLR signaling, we first exposed DCs to IL-6 and then stimulated with LPS (Figure 
4.2).  BMDCs from B6 and MRL/lpr mice were pre-treated with IL-6 for 30 minutes, then 
stimulated with LPS for the indicated times.  The effect of IL-6 on TLR signaling was 
determined by immunoblotting whole cell lysates for phospho-IB. The data showed that 
prior exposure to IL-6 in B6 DCs may enhance IB phosphorylation in response to LPS 
compared to B6 DCs stimulated with LPS alone.  In contrast, prior exposure to IL-6 in 
MRL/lpr DCs decreased LPS-induced IB phosphorylation in compared to LPS stimulation 
alone.  Thus, LPS signaling in lupus DCs exhibit a negative response to IL-6, whereas IL-6 
may have a positive feedback on TLR signaling in nonautoimmune DCs.  The data suggest 
that the IL-6 produced by lupus DCs in culture could act in an autocrine manner to prevent 
further signal transduction through the TLR.   
MRL/lpr DCs are somehow responding differently to IL-6.  IL-6 binding to its 
receptor activates the JAK-STAT signaling pathway.  Receptor dimerization induces 
phosphorylation of JAK, which recruits and phosphorylates STAT3.  Phosphorylated STAT3 
dimerizes and translocates to the nucleus to function as a transcription factor.  To determine 
95
whether differences exist in IL-6 signaling in MRL/lpr DCs compared to B6 DCs, we 
immunoblotted whole cell lysates for phosphorylated STAT3 (Figure 4.3).  Unstimulated B6 
DCs exhibited very little basal phospho-STAT3.  IL-6 stimulation induced phosphorylation 
of STAT3 peaking at 15 minutes and then diminishing thereafter.  MRL/lpr DCs exhibited a 
similar pattern of STAT3 phosphorylation, however, significant basal levels of phospho-
STAT3 indicated the presence of aberrantly activated STAT3.  Phosphorylation of STAT3 
was further enhanced by IL-6 stimulation with STAT3 protein levels similar to B6 DCs.  
Thus, the data suggest that MRL/lpr DCs have a hyperactive JAK-STAT signaling pathway.  
Figure 4.2 showed that prior exposure to IL-6 in MRL/lpr DCs decreased LPS-induced IB
phosphorylation.  Consequently, the aberrantly activated STAT3 in MRL/lpr DCs could be 
negatively affecting TLR signaling.  Future experiments to confirm that IL-6 and STAT3 
signaling pathways inhibit TLR signaling would involve blocking these pathways in 
MRL/lpr DCs to determine their effect on TLR signaling.  IL-6 signaling can be inhibited by 
using an IL-6 receptor antibody blocking, and STAT3 signaling can be blocked by using the 
STAT3 pharmacological inhibitor JSI-124.  We predict that TLR signaling in MRL/lpr DCs 
would be enhanced or sustained to a greater extent if IL-6 and STAT3 signaling are inhibited. 
The molecular mechanism as to how IL-6 stimulation or hyperactive STAT3 could 
inhibit TLR signaling is unclear.  IL-6 and LPS induce SOCS1 and SOCS3 in a STAT 
dependent or independent manner, and SOCS proteins prevent LPS induced cytokine 
production (111-113, 115-117).  SOCS3 is the major SOCS protein induced by IL-6, 
although SOCS1 can also be stimulated.  To determine if hyperactivated STAT3 translated 
into increased expression of SOCS proteins, SOCS1 and SOCS3 mRNA levels were 
measured in IL-6-stimulated BMDCs using real time RT-PCR (Figure 4.4).  The data show 
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that IL-6 induced increased peak levels of SOCS1 mRNA at 15 minutes in MRL/lpr DCs 
compared to B6 DCs, but similar amounts of RNA transcripts were produced thereafter 
(Figure 4.4A).  In contrast, IL-6 induced increased peak levels at 15 minutes and increased 
sustained amounts of SOCS3 mRNA out to 2 hours in MRL/lpr DCs (Figure 4.4B).  Thus, 
hyperactive STAT3 translates into increased expression of SOCS transcription.  It remains to 
be determined whether SOCS protein levels correlate with this trend. 
In summary, MRL/lpr DCs quickly become tolerized to LPS causing defective 
production of TLR-stimulated cytokines.  SOCS proteins are involved in the regulation of 
LPS-induced cytokine production (111-113, 115-117).  We show here that prior exposure to 
IL-6 diminished TLR signaling in MRL/lpr DCs, coincident with hyperactive STAT3 and 
SOCS1 and SOCS3 gene expression.  These findings present the possibility that 
STAT3/SOCS are involved in the excessive negative regulation of TLR responses in 
MRL/lpr DCs. 
A previous study linked hyperactive STAT3 signaling to lupus.  Liu et al have found 
that B cells from mice expressing the Sle1ab lupus susceptible locus produce antinuclear 
antibodies mediated by hyperactive STAT3 and ras-ERK signaling pathways (70).  These B 
cells also exhibit increased expression of SOCS3.  Significantly, we show here that DCs from 
MRL/lpr mice exhibit hyperactive STAT3 and increased SOCS3 expression, coincident with 
the inability to sustain TLR signaling and cytokine production and regulate autoantibody 
secretion.  Thus, the STAT3/SOCS3 phenotype present in lupus DCs is similar to lupus B 
cells.  The next step is to determine how hyperactive STAT3 and increased SOCS3 affect 
TLR signaling and whether this defect affects TLR tolerance in MRL/lpr DCs. 
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Little is known about the mechanisms of how SOCS proteins inhibit TLR signaling.  
Frobose et al showed that SOCS3 inhibits IL-1 signal transduction by inhibiting 
ubiquitination of TRAF6, thus preventing association and activation of TAK1 (118).  SOCS1 
inhibition of LPS signaling involves several mechanisms.  SOCS1 associates with TLR 
molecules IRAK (111) and Mal (116).  SOCS1 also inhibits phosphorylation of Jak2 and 
STAT5 involved in NF-B activation (119).  Further experiments are necessary to determine 
the role of SOCS proteins in regulating TLR responses in MRL/lpr DCs.  Co-
immunoprecipitation can be used to determine whether SOCS proteins interact with TLR 
signaling molecules.  In addition, siRNA can be used to inhibit newly transcribed SOCS 
mRNA.  Due to the rapid turnover of SOCS proteins (233), we expect there will be very little 
basal SOCS present.  Thus, siRNA will inhibit SOCS activity in MRL/lpr DCs.  We predict 
these experiments will show that in the absence of SOCS activity TLR signaling will be at 
least partially restored.  Alternatively, the absence of restored TLR responses will be difficult 
to interpret.  This result could be due to the lack of involvement of SOCS or compensation by 
any one of the several negative regulators of TLR signaling. 
We have presented some evidence suggesting the involvement of STAT3/SOCS in 
the excessive regulation of TLR signaling in MRL/lpr DCs.  However, it is important to 
investigate another important regulatory mechanism for TLR signaling associated with lupus.  
DCs and Ms exposed to apoptotic cells are unable to respond to TLR stimulation (149) 
(Sykes and Matsushima, unpublished observations).  Lupus in humans and mice is associated 
with an increased burden of apoptotic cells (14-16, 57, 58), and mice lacking receptor 
tyrosine kinases important in phagocytosis of apoptotic cells develop lupus (59-62).  Thus, 
prolonged exposure to apoptotic cells in vivo could affect the ability of DCs and Ms to 
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sustain TLR responses needed to produce repressive soluble factors.  In fact, Koh et al 
described apoptotic cell inhibition of TLR signaling in Ms from several strains of lupus-
prone mice without understanding how the lack of inflammatory cytokines related to the 
break in B cell tolerance and lupus disease (158).  Thus, there are several directions to take 
this investigation.  Determining the cause of the TLR defect in lupus-prone mice could 
identify a genetic signature for individuals susceptible to lupus disease and make a 
significant contribution to the field. 
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Figure 4.1.  Lupus DCs exhibit defects in IRAK1 expression. BMDCs (2x106) from B6 
or MRL/lpr mice were stimulated with LPS (15 µg/ml) for the indicated timepoints. IRAK1 
or actin expression in whole cell lysates was determined by immunoblotting.  Data represent 
3 experiments. 
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Figure 4.2.  IL-6 affects TLR4 signaling in DCs. BMDCs (2x106) from B6 or MRL/lpr 
mice were pre-treated with recombinant IL-6 (10 ng/ml) for 30 minutes then stimulated with 
LPS (15 µg/ml) for the indicated timepoints.  Phospho-IB, IB, and  tubulin expression 
in whole cell lysates was determined by immunoblotting.  Data represent 3 experiments. 
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Figure 4.3. Lupus DCs exhibit aberrantly activated STAT3. BMDCs (2x106) from B6 or 
MRL/lpr mice were stimulated with IL-6 (10 ng/ml) for the indicated timepoints.  Phospho-
STAT3 Y705, STAT3, and  tubulin expression in whole cell lysates was determined by 
immunoblotting.  Data represent 3 experiments. 
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Figure 4.4.  IL-6 induces increased expression of SOCS proteins in lupus DCs. BMDCs 
(2x106) from B6 () or MRL/lpr () mice were stimulated with IL-6 (10 ng/ml) for the 
indicated timepoints.  Real time RT-PCR was performed on RNA isolated from DCs.  
SOCS1 and SOCS3 mRNA levels were quantitated and plotted as fold over background in 
unstimulated DCs.  Data represent at least 4 experiments.
 
CHAPTER V 
Discussion
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The ability to mount immune responses to infectious agents is critical in surviving 
and adapting to surrounding environments.  Innate immunity has evolved to quickly and 
nonspecifically control the invasion and pathogenesis of microbes before the adaptive 
immune response can generate a targeted defense and memory against the infectious agent.  
The nonspecific response during innate immunity is effective in the early control of 
infection; however unregulated, polyclonal activation of immune cells can disrupt the 
balance between immunity and tolerance to self-antigens.  Thus, polyclonal activation could 
promote autoimmunity in individuals susceptible to diseases like lupus. 
The regulation of autoreactive lymphocytes during innate immune responses is 
important in understanding the breakdown of tolerance that occurs in lupus.  We propose a 
model where autoreactive B cells that chronically see antigen are repressed during polyclonal 
activation and maintained in an anergic state, while naïve B cells are allowed to mount a 
response.  We recently identified a novel mechanism of tolerance wherein DCs and Ms
repress Ig secretion by autoreactive B cells (160).  Polyclonal activators through TLRs 
induce DCs and Ms to secrete soluble factors (IL-6, sCD40L, and TNF) that differentially 
regulate naïve and chronically antigen-experienced B cells.  Significantly, IL-6, sCD40L, and 
TNF selectively repress LPS-stimulated autoreactive B cells while having no effect on 
naïve B cells (160) (Kilmon et al, manuscript submitted; Chapter 3).  Thus, we have 
identified a mechanism that prevents autoimmunity while allowing naïve B cells to respond 
during innate immune responses. 
The data indicating that DCs and Ms mediate tolerance through the secretion of IL-
6, sCD40L, and TNF may seem paradoxical at first glance.  Myeloid DCs (myDCs) and 
plasmacytoid DCs (pDCs) have been described as positive regulators of immunity promoting 
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growth and differentiation of some B cells through the secretion of IL-12, IL-6, BLyS, and 
APRIL (139, 140, 174).  Specifically, IL-6 was found to promote plasma cell survival (175, 
176).  CD40L is required for activation of B cells in response to T-dependent antigens (38).  
Soluble TNF enhances cytokine or mitogen-stimulated B cell proliferation and antibody 
secretion (209-213, 234).  Membrane-bound TNF expressed on viral-infected T cells 
mediates polyclonal B cell activation (214, 215).  Studies identifying IL-6 and TNF as 
positive regulators focused on B cells from non-transgenic mice where the proportion of 
autoreactive cells is low.  In contrast, the studies showing that IL-6, sCD40L, and TNF
repress autoantibody production used self-reactive Ig transgenic models where the B cells 
were constantly exposed to self-antigen (160) (Kilmon et al, manuscript submitted; Chapter 
3).  This effect is not limited to Ig transgenic B cells because autoreactive B cells from B6 
mice are repressed by sCD40L.  Thus, IL-6, sCD40L, and TNF act as positive or negative 
regulators of B cells depending on the history of BCR ligation. 
We propose that chronic BCR ligation by self-antigen reprograms IL-6, sCD40L, and 
TNF receptor-mediated outcomes allowing naïve B cells to produce Ig in response to 
polyclonal stimulation while simultaneously repressing autoreactive B cells from producing 
autoantibody.  Ig repression by IL-6 and sCD40L in chronically antigen-experienced B cells 
involves mechanisms upstream of Blimp-1 and XBP-1 expression.  IL-6, sCD40L, and 
TNF do not affect LPS-induced proliferation, but IL-6 and sCD40L inhibit the 
differentiation of B cells to antibody secreting plasma cells (Rutan et al, manuscript in 
preparation; Kilmon et al, manuscript submitted).  Other studies have shown that IL-6 
represses Ig secretion by an ERK-dependent mechanism (Rutan et al, manuscript in 
preparation).  Thus, chronic BCR stimulation induces ERK activation that reprograms the IL-
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6 response.  As a result, instead of IL-6 promoting plasma cell differentiation, IL-6 prevents 
plasma cell differentiation in LPS-stimulated chronically antigen-experienced B cells. 
Not only is the history of BCR ligation critical in determining whether B cells are 
susceptible to IL-6, CD40L, and TNF-mediated repression, but the data suggest that BCR 
affinity is also important in this fate decision.  TNF repressed Ig secretion by low affinity, 
Sm-specific B cells, but did not affect Ig secretion by high affinity (>109 M), HEL-specific B 
cells chronically exposed to soluble HEL (HEL-Ig x sHEL) (Chapter 3).  TNF is less potent 
as a repressive factor than IL-6 and sCD40L.  Consequently, TNF may not be strong 
enough to repress B cells with high affinity BCR specific for self-antigen.  To confirm this 
hypothesis, we plan to test the ability of TNF to repress autoreactive B cells from other low 
affinity Ig transgenic models.  One potential model is the anti-insulin 125 Ig transgenic 
model.  Similar to anti-Sm 2-12H/V8 Ig transgenic B cells, 125 Ig transgenic B cells 
express a BCR with low affinity for self-antigen (107 M) (216).  These B cells do not 
undergo developmental arrest, but are anergic in the periphery and have characteristics of a 
B1-like subset (217, 218).  Significantly, SLE patients have higher frequencies of serum anti-
insulin IgM antibodies than healthy controls (219).  Thus, the anti-insulin Ig transgenic 
model having a low affinity BCR should prove useful in studying tolerance mediated by 
TNF.
Neutralization studies suggest that all of the repressive soluble factors have been 
identified.  IL-6-/- DC conditioned media (CM) and IL-6-/- x CD40L-/- M CM were just as 
capable of repressing chronically antigen-experienced B cells as DC CM and M CM from 
B6 mice.  Neutralizing TNF in IL-6-/- DC CM and IL-6-/- x CD40L-/- M CM relieved the 
repressive effect (DCs do not express CD40L) (Chapter 3).  Hence, the data suggest that 
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TNF is responsible for Ig repression in the absence of IL-6 and sCD40L.  However, 
recombinant TNF could not repress the majority of Ig secretion like IL-6 and sCD40L.  
Thus, a cofactor secreted by DCs and Ms may exist that allows TNF to exert its full 
repressive potential on chronically antigen-experienced B cells.  This cofactor is not capable 
of repression alone, as IL-6-/- x TNF-/- DC CM did not repress Ig secretion (Chapter 3).  We 
expect that future experiments will also show that IL-6-/- x CD40L-/- x TNF-/- M CM do 
not repress Ig secretion.  It would be interesting to determine whether the possible cofactor is 
secreted by IL-6-/- x TNF-/- DCs and present in CM.  If so, we would predict that the 
cofactor in IL-6-/- x TNF-/- DC CM could restore the full repressive potential of rTNF, and 
that autoreactive B cells cultured in the presence of IL-6-/- x TNF-/- DC CM and rTNF
would repress Ig secretion similar to B6 DC CM. 
The findings that three different factors repress Ig secretion suggest redundancy in 
function.  Certainly, the regulation of autoreactive B cells is important enough to have back-
up mechanisms.  This is the reason that several mechanisms of tolerance exist at different 
checkpoints of B cell development, activation, and differentiation.  However, we have seen 
some differences in the ability of IL-6 and sCD40L to regulate different subsets of B cells.  
CD40L represses follicular and marginal zone B cells from 2-12 heavy chain Ig transgenic 
mice, whereas IL-6 represses only follicular B cells (Kilmon et al, manuscript submitted).  
Thus, the functions of IL-6 and CD40L are not completely redundant.  Future experiments 
will determine the ability of these factors to repress pre-plasma cell and B1 subsets.  In 
addition, we will determine the ability of IL-6, sCD40L, and TNF to repress An1 positive 
naturally occurring anergic B cells in B6 mice. 
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In addition to tolerance mediated by repressive soluble factors, data indicate that a 
contact-mediated mechanism regulates Ig secretion.  DC CM is less efficient at repressing Ig 
secretion compared to intact DCs indicating that a contact-dependent mechanism may 
partially regulate Ig secretion.  In support of this, DCs deficient in TLR4 are unable to secrete 
repressive factors in response to LPS, yet they partially repress Ig secretion.  However, 
repression is lost when DCs are separated from B cells by transwell apparatus (Kilmon and 
Vilen, unpublished observations).  DCs display intact nuclear antigen on their surface and 
chronic antigen/BCR stimulation maintains B cells in an anergic state.  Thus, the contact-
mediated mechanism may involve antigen displayed on DCs.  Alternatively, DCs interacting 
with B cells may engage inhibitory receptors that regulate BCR and/or TLR responses.  
Recent adaptation of 2-photon microscopy to visualize live interaction of cells in vivo now
makes it feasible to determine whether DCs interact with autoreactive B cells in vivo.
During innate immune responses, autoimmunity could result if DC and M defects 
diminish the secretion of repressive soluble factors or if autoreactive B cells are unable to 
differentially respond to repressive factors.  Therefore, we hypothesize that DC and/or M-
mediated tolerance mechanisms are dysfunctional in murine models of lupus disease.  We 
showed that MRL/lpr-derived DCs, Ms, and their secreted factors were defective in 
repressing Ig secretion, coincident with defective secretion of IL-6, sCD40L, and TNF. It 
remains to be determined whether autoreactive B cells from lupus-prone mice can be 
repressed by IL-6, sCD40L, and TNF. Preliminary studies suggest that autoreactive B cells 
from 2-12 heavy chain Ig transgenic MRL and MRL/lpr mice are not repressed by IL-6, 
sCD40L, and TNF. This would suggest that autoreactive B cells from lupus-prone mice 
fail to reprogram IL-6, sCD40L, and TNF receptors to signal the repression of TLR 
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responses.  Thus, one or more defects in DC/M-mediated tolerance could lead to 
autoimmunity and lupus disease in vivo.
Investigation into the mechanism of the TLR defect in lupus DCs demonstrates their 
inability to sustain signaling through the TLR.  The data suggest that lupus DCs quickly 
become tolerized to LPS.  Endotoxin tolerance is a normal regulatory mechanism controlling 
cellular responses to bacterial products.  Upon ligand binding, MyD88 associates with the 
TLR and recruits IRAK4 and IRAK1.  Activation of IRAK1 leads to downstream 
phosphorylation of IB, NF-B activation, and transcription of cytokines.  Endotoxin 
tolerance is associated with a reduction in IRAK1 expression, IRAK association with 
MyD88, and IB phosphorylation (231, 232).  Thus far, we have determined that MRL/lpr 
DCs exhibit decreased IRAK1 expression (Chapter 4) and decreased ability to sustain IB
phosphorylation (208) in response to LPS.  Thus, endotoxin tolerance may chronically 
disable MRL/lpr DCs making them inefficient at IL-6 and TNF secretion.  Determining the 
TLR defect in DCs and Ms from lupus-prone mice could identify a genetic signature for 
individuals susceptible to lupus disease.  There are several negative regulators of TLR 
signaling that could play a role in this phenomenon.  However, only a few of them have been 
associated with autoimmune disease, including apoptotic cells and SOCS proteins.  
DCs and Ms exposed to apoptotic cells are unable to respond to TLR stimulation 
(149) (Sykes and Matsushima, unpublished observations).  Lupus in humans and mice is 
associated with an increased burden of apoptotic cells (14-16, 57, 58), and mice lacking 
receptor tyrosine kinases important in phagocytosis of apoptotic cells develop lupus (59-62).  
Thus, prolonged exposure to apoptotic cells in vivo could affect the ability of DCs and Ms
to sustain TLR responses needed to produce repressive soluble factors.  In fact, Koh et al 
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described apoptotic cell inhibition of TLR signaling in Ms from several strains of lupus-
prone mice without understanding how the lack of inflammatory cytokines related to the 
break in B cell tolerance and lupus disease (158). 
SOCS proteins negatively regulate LPS signaling.  Liu et al have found that B cells 
from mice expressing the Sle1ab lupus susceptible locus produce antinuclear antibodies 
mediated by hyperactive STAT3 and ras-ERK signaling pathways (70).  These B cells also 
exhibit increased expression of SOCS-3.  Significantly, we have found that DCs from 
MRL/lpr mice exhibit hyperactive STAT3 and increased SOCS3 expression (Chapter 4), 
coincident with the inability to sustain TLR signaling and cytokine production and regulate 
autoantibody secretion.  Thus, the STAT3/SOCS3 phenotype present in lupus DCs is similar 
to lupus B cells.  The next step is to determine if hyperactive STAT3 and increased SOCS3 
dysregulate TLR signaling in MRL/lpr DCs.  Whether STAT3/SOCS3 or apoptotic cells are 
inducing this response has yet to be determined. 
To establish if DC/M-mediated tolerance is important in disease, it is necessary to 
determine whether the lack of IL-6, sCD40L, and TNF causes disease in nonautoimmune 
mice or whether functional DCs and Ms can prevent onset or reverse disease in 
autoimmune mice.  In vitro data suggest that the lack of repressive soluble factors would 
cause disease in nonautoimmune mice.  However, it is difficult to predict the effect of IL-6, 
CD40L, and TNF deficiencies on autoimmunity in triple knock-out mice for several 
complicating reasons.  First, TNF is important for proper formation of the splenic 
architecture (221, 222).  TNF is required for the formation of primary B cell follicles, 
follicular DC networks, and germinal centers.  Secondly, CD40L is important in generating 
class-switched IgG pathogenic autoantibodies that cause disease.  As a result, the presence or 
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absence of autoimmune disease in IL-6-/- x CD40L-/- x TNF-/- mice is difficult to interpret.  
The presence of autoimmunity in triple knock-out mice could be contributed to the lack of 
repressive factors that regulate autoreactive B cells in the periphery.  Alternatively, the 
presence of autoimmunity could be due to disruption of the splenic architecture such that 
autoreactive B cells are not in the proper location in the spleen to be regulated by extrinsic 
tolerance mechanisms other than IL-6, CD40L, and TNF. Likewise, the absence of 
autoimmunity in triple knock-out mice could be contributed to disruption of the splenic 
architecture such that autoreactive B cells are not able to receive survival signals provided by 
follicular dendritic cells in the B cell follicle.  Another possible scenario is that autoimmunity 
would result without disease.  Although the splenic architecture would be disrupted due to 
the lack of TNF, IgM responses are unaffected in TNF-/- mice.  Despite the absence of B 
cell follicles, Ig class-switching can still occur, yet deregulated IgG responses are evident 
(221).  However, the lack of CD40L could prevent the development of IgG class-switched 
autoantibodies that cause disease.  Therefore, IgM autoantibodies could result without the 
presence of disease in triple knock-out animals.  Thus, the absence of autoimmunity or 
disease in triple knock-out mice would not prove that IL-6, CD40L, and TNF are not 
important in regulating autoreactive B cells in vivo.
The proper formation of splenic follicles and germinal centers is a significant variable 
in studying autoimmunity in IL-6-/- x CD40L-/- x TNF-/- mice.  To eliminate disrupted 
splenic architecture as a variable, we propose to transplant stem cells from IL-6-/- x CD40L-/- 
x TNF-/- mice into irradiated wildtype nonautoimmune mice.  This would generate IL-6, 
CD40L, and TNF deficient immune cells in the context of a properly structured spleen.  We 
could then adoptively transfer Ig transgenic autoreactive B cells into these mice and follow 
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their break in tolerance by the presence of Ig transgenic autoantibody in the serum.  This 
experiment would prove that autoreactive B cells are regulated by IL-6, CD40L, and TNF
in vivo and that the lack of repressive soluble factors causes a break in tolerance. 
The experiments described above do not address the source of the repressive factors 
in vivo. Thus, they would not directly address the role of DCs and Ms in regulating 
autoimmunity.  The only way to determine the role of DC and M-derived IL-6, CD40L, 
and TNF is to create a DC and M conditional knock-out mouse for IL-6, CD40L, and 
TNF. Using the cell specific conditional knock-out would allow for the proper formation of 
the splenic architecture and restrict the deficiency of the repressive factors to DCs and Ms.  
Although this mouse would be a useful tool, it would not be a trivial task to create. 
Future experiments will determine whether functional DCs and Ms can prevent 
onset or reverse disease in lupus-prone mice.  Bone marrow transplantion has been used to 
prevent and treat lupus in MRL/lpr mice.  Total body irradiation, transplantation of 
allogeneic B6 bone marrow, plus bone grafts supplying stromal cells successfully prevent the 
development of autoimmune disease in young MRL/lpr mice (235).  However, MRL/lpr 
mice after the onset of disease do not survive this regimen because they become extremely 
radiosensitive and susceptible to uremic enterocolitis.  Therefore, bone marrow 
transplantation involving fractionated total body irradiation is used instead and results in 
survival of the mice and treatment of lupus disease (220).  This experiment can be modified 
to study the role of the repressive soluble factors in preventing disease.  B6 bone marrow 
transplantation protects MRL/lpr mice from disease.  Thus, if hematopoietic stem cells from 
IL-6-/- x CD40L-/- x TNF-/- are transplanted into irradiated MRL/lpr mice, we would predict 
from in vitro data that the mice will not be protected from disease because they lack the 
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repressive soluble factors that regulate autoreactive B cells.  Because wildtype stem cell 
transplantion protects from lupus, this data would suggest that the lack of IL-6, CD40L, and 
TNF causes disease. 
The ultimate goal of understanding B cell tolerance mechanisms is to create more 
specific clinical therapies for the prevention and treatment of disease.  Interestingly, the use 
of antibodies against IL-6, TNF, and CD40L has been studied for the treatment of lupus for 
good reason.  IL-6, TNF, and CD40L all promote B cell activation, differentiation, and Ig 
production as previously described.  In addition, IL-6 and TNF are proinflammatory 
cytokines that cause tissue damage.  Significantly, lupus patients with active disease have 
increased serum concentrations of IL-6, TNF, and CD40L.  Thus, it was logical to think 
that blocking their actions would decrease autoreactive B cell activation and symptoms of 
disease.  However, our data suggest that these therapies would promote the break in tolerance 
of newly generated autoreactive B cells because IL-6, TNF, and CD40L repress chronically 
antigen-experienced B cells.  As a matter of fact, anti-TNF therapy has been found to cause 
lupus-like symptoms in several cases.  Yet, the findings that lupus patients with active 
disease have increased serum concentrations of IL-6, TNF, and CD40L seem contradictary 
to our data.  Preliminary studies suggest that lupus autoreactive B cells are not repressed by 
IL-6, sCD40L, and TNF. Thus, once B cells break tolerance in lupus patients, they may no 
longer be able to respond appropriately to the increased serum concentrations of repressive 
factors.  It would be interesting to determine whether autoreactive B cells from lupus mice 
pre-disease are capable of being repressed by the soluble factors and if this corresponds with 
normal serum levels of IL-6, sCD40L, and TNF.
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The goals of therapy are to eliminate autoreactive B cells and/or restablish tolerance 
in autoreactive B cells.  Currently, the standard of care for SLE is immunosuppressive or 
anti-inflammatory drugs, with recent therapies focusing on B cell depletion.  Rituximab, the 
anti-CD20 monoclonal antibody that depletes B cells, has been used to treat lupus with some 
success for the last decade.  The antibody depletes all B cells except antibody secreting 
plasma cells, yet some patients respond with better clinical outcomes.  The rationale for B 
cell depletion is obviously to rid the immune repertoire of B cells that produce pathogenic 
antibodies.  However, B cell depletion could also be used as a reset button, allowing bone 
marrow stem cells to regenerate the B cell repertoire.  In conjunction, drugs that regulate 
autoreactive B cells could supplement B cell depletion to maintain tolerance of newly 
generated autoreactive B cells that escape central tolerance and enter the periphery.  As more 
therapies are created to maintain tolerance of autoreactive B cells, the supplement to B cell 
depletion can be catered to the patient.  This combination therapy would provide a more 
individualized treatment in comparison to the general immunosuppressive drugs. 
The balance between immunity and tolerance is a very intricate system.  Our work 
challenges the roles of DCs, Ms, IL-6, CD40L, and TNF in this balance.  We submit that 
these cells and soluble factors are both positive and negative regulators of B cell activation 
and antibody production.  Pleiotropic function of cells and cytokines in the immune system is 
not uncommon and depends on timing, location, and environment.  For example, Ms act as 
chronic inflammatory cells and are important in the resolution of inflammation.  DCs are 
very efficient at priming T cell responses and can induce T cell tolerance (145, 146, 236).  
TNF and CD40L have the potential to block or induce apoptosis depending on the cellular 
context (237, 238).  Although new treatments have been helpful in many autoimmune 
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patients, we caution the use of anti-IL-6, CD40L, and TNF therapies as their side effects 
may involve lupus-like symptoms in the long-term. 
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